Marathon Digital (MARA) 10-Q 16 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 01, 2015
Document And Entity Information
Entity Registrant Name	Marathon Patent Group, Inc.
Entity Central Index Key	1,507,605
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		14,867,141
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 3,408,839	$ 5,082,569
Accounts receivable - net of allowance for bad debt of $0 and $0 for September 30, 2015 and December 31, 2014	2,326,717	216,997
Bonds posted with courts	1,794,226	1,946,196
Prepaid expenses and other current assets, net of discounts of $3,414 and $0 for September 30, 2015 and December 31, 2014	114,953	438,391
Total current assets	7,644,735	7,684,153
Other assets:
Property and equipment, net of accumulated depreciation of $55,571 and $16,135 for September 30, 2015 and December 31, 2014	70,680	53,828
Intangible assets, net of accumulated amortization of $14,931,649 and $6,550,528 for September 30, 2015 and December 31, 2014	43,753,217	43,363,832
Deferred tax assets	10,529,693	4,789,293
Other non current assets, net of discounts $5,760 and $0 for September 30, 2015 and December 31, 2015	11,238
Goodwill	4,573,450	4,894,208
Total other assets	58,938,278	53,101,161
Total Assets	66,583,013	60,785,314
Current liabilities:
Accounts payable and accrued expenses	8,992,574	3,293,746
Clouding IP earn out - current portion	327,757	2,092,000
Notes payable, net of discount of $703,762 and $82,010 for September 30, 2015 and December 31, 2014	19,384,416	16,560,000
Total current liabilities	28,704,747	21,945,746
Long-term liabilities
Notes payable, net of discount and loan fees of $1,617,885 and $64,925, for September 30, 2015 and December 31, 2014	13,876,928	5,403,065
Other non current liability	51,092
Deferred tax liability	1,056,406	1,823,884
Revenue sharing liability	1,000,000
Clouding IP earn out - long-term portion	6,222,895	7,360,000
Total long-term liabilities	22,207,321	14,586,949
Total liabilities	50,912,068	36,532,695
Stockholders' equity:
Preferred stock Series B, $.0001 par value, 50,000,000 shares authorized: 798,670 and 932,000 issued and outstanding at September 30, 2015 and December 31, 2014	80	93
Common stock, $.0001 par value, 200,000,000 shares authorized: 14,550,475 and 13,791,460 issued and outstanding at September 30, 2015 and December 31,2014	1,456	1,379
Additional paid-in capital	42,014,873	36,977,169
Accumulated other comprehensive loss	(973,063)	(388,357)
Accumulated deficit	(25,372,401)	(12,337,665)
Total stockholders' equity	15,670,945	24,252,619
Total liabilities and stockholders' equity	$ 66,583,013	$ 60,785,314

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance for bad debt	$ 0	$ 0
Prepaid Expenses	3,414	0
Accumulated depreciation of property and equipment	55,571	16,135
Accumulated amortization of Intangible assets	14,931,649	6,550,528
Discount on other noncurrent assets	5,760	0
Current liabilities:
Notes payable, net	703,762	82,010
Long-term liabilities
Notes payable, net	$ 1,617,885	$ 64,925
Stockholders' Equity:
Preferred stock Series B, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	798,670	932,000
Preferred stock, shares outstanding	798,670	932,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	14,550,475	13,791,460
Common stock, shares outstanding	14,550,475	13,791,460

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Revenue	$ 6,407,997	$ 13,455,472	$ 11,870,851	$ 20,059,972
Expenses
Cost of revenues (cost of revenues is exclusive of patent amortization expenses)	4,002,040	5,584,542	12,190,415	8,448,954
Amortization of patents	2,884,269	1,480,311	8,511,730	2,872,638
Compensation and related taxes	903,685	824,165	3,571,817	2,266,283
Consulting fees	643,702	785,601	1,869,326	1,550,155
Professional fees	882,213	408,280	2,230,748	933,751
General and administrative	177,494	166,216	681,951	380,400
Impairment of patent			766,498
Impairment of goodwill		2,144,488		2,144,488
Total operating expenses	9,493,403	11,393,603	29,822,485	18,596,669
Operating income (loss)	(3,085,406)	2,061,869	(17,951,634)	1,463,303
Other income (expenses)
Other income/(expense)	6,646	(21,063)	14,085	(21,833)
Foreign exchange gain/(loss)	(20,090)	256	(57,593)	256
Change in fair value adjustment of Clouding IP earn out	597,047		2,901,348
Interest income	135	138	137	632
Interest expense	(1,078,615)		(3,587,238)	(20)
Loss on debt extinguishment	(654,000)		(654,000)
Total other expesnes	(1,148,877)	(20,669)	(1,383,261)	(20,965)
Income (Loss) before benefit for income taxes	(4,234,283)	2,041,200	(19,334,895)	1,442,338
Income tax benefit	483,815	1,481,404	6,300,159	1,481,404
Net income (loss)	(3,750,468)	3,522,604	(13,034,736)	2,923,742
Deemed dividends to related beneficial conversion feature of Series A preferred stock				(1,271,492)
Net income (loss) attributable to common shareholders	$ (3,750,468)	$ 3,522,604	$ (13,034,736)	$ 1,652,250
Earnings (Loss) Per Share, Basic	$ (0.26)	$ 0.31	$ (0.92)	$ 0.15
Earnings (Loss) Per Share, Diluted	$ (0.26)	$ 0.22	$ (0.92)	$ 0.11
Weighted-Average Number of Shares Outstanding - Basic	14,376,118	11,500,500	14,094,891	11,197,374
Weighted Average Number of Shares Outstanding - Diluted	14,376,118	15,966,454	14,094,891	14,926,504
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	$ 45,628		$ (584,706)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Statement of Cash Flows [Abstract]
Net income (loss)	$ (13,034,736)	$ 2,923,742
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation	5,668	4,357
Amortization of intangible assets	8,511,730	2,872,638
Amortization of expenses connected to equity to be issued for services		355,711
Net reversal of expense related to forfeiture of unvested stock		(179,708)
Impairment of goodwill		2,144,488
Deferred tax assets	(5,579,418)	(1,949,401)
Income tax payable		467,997
Deferred tax liability	(709,280)
Impairment of patent	766,498
Loss on debt extinguishment	654,000
Stockbased compensation	1,961,505	2,101,995
Stock issued for services	1,084,834
Non-cash interest, discounts and financing costs	1,926,865
Change in fair value of Clouding earn-out	(2,901,348)
Non-cash other income		(3,930)
Other non-cash adjustments	(13,244)	24,994
Changes in operating assets and liabilities
Accounts receivable	(2,109,984)	(10,182,950)
Prepaid expenses and other current assets	60,938	(207,182)
Accounts payable and accrued expenses	6,454,467	4,860,286
Net cash provided by (used in) operating activities	(2,921,505)	3,233,037
Cash flows from investing activities:
Acquisition of patents		(6,850,800)
Purchase of property, equipment and other intangible assets	(22,520)	(24,903)
Net cash provided by (used in) investing activities	(22,520)	(6,875,703)
Cash flows from financing activities:
Payment on note payable in connection with the acquisition of IP Liquidity	(1,109,375)	(937,500)
Payment on note payable in connection with the acquisition of Dynamic Advances	(2,624,375)
Payment on assumed note payable in connection with the acquisition of Orthophoenix	(5,000,000)
Payment on note payable in connection with the acquisition of Medtech and Orthophoenix	(4,200,000)
Payment on Due to MdR Escrow (TLI)	(50,000)
Payment on note payable in connection with the acquisition of Sarif	(276,250)
Repayment on convertible notes	(5,050,000)
Repayment of notes payable to vendors	(42,500)
Cash received upon issuance of notes payable (net of issuance costs)	19,600,000
Proceeds received from sale of Preferred Stock / common stock, net of issuance costs		6,388,266
Cash received upon exercise of warrant	18,751	138,222
Net cash provided by financing activities	1,266,251	5,588,988
Effect of exchange rate changes on cash	4,044
Net increase (decrease) in cash	(1,673,730)	1,946,322
Cash at beginning of period	5,082,569	3,610,262
Cash at end of period	3,408,839	5,556,584
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for: Interest expenses and loan fees	1,660,372	20
Cash paid for: Taxes paid	54,437
Loan fees	400,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Common stock issued in connection with the acquisition of Clouding Corp.		281,000
Earn-out liabilities in connection with the acquisition of Clouding Corp.		13,119,000
Common stock granted in connection with the acquisition of TLI Communications, LLC		817,800
Series B Preferred Stock issued in connection with the acquisition of Dynamic Advances, LLC		1,403,690
Series B Preferred Stock issued in connection with the acquisition of IP Liquidity Ventures, LLC		1,403,690
Common stock issued in connection with the acquisition of Selene Communication Technologies, LLC		980,000
Value of warrants pertaining to equity issuance		11,595
Notes payable in connection with the acquisition of Dynamic Advances, LLC, IP Liquidity Ventures, LLC, and Selene Communication Technologies, LLC		7,000,000
Common stock issued for prepaid services		$ (298,301)
Common stock issued in conjunction with note payable	1,000,000
Warrants issued in conjunction with note payable	318,769
Revenue share liability incurred in conjunction with note payable	1,000,000
Non-cash interest increase in debt assumed in the acquisition of Orthophoenix	750,000
Notes payable issued in conjunction with acquisition of BATO patent	10,000,000
Common stock issued in conjunction with debt extinguishment	654,000
Conversion of accounts payable to note payable	$ 705,093

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Organization We acquire patents and patent rights from owners or other ventures and seek to monetize the value of the patents through litigation and licensing strategies, alone or with others. Part of our acquisition strategy is to acquire or invest in patents and patent rights that cover a wide-range of subject matter which allows us to seek the benefits of a diversified portfolio of assets in differing industries and countries. Generally, the patents and patent rights that we seek to acquire have large identifiable targets who are or have been using technology that we believe infringes our patents and patent rights. We generally monetize our portfolio of patents and patent rights by entering into license discussions, and if that is unsuccessful, initiating enforcement activities against any infringing parties with the objective of entering into comprehensive settlement and license agreements that may include the granting of non-exclusive retroactive and future rights to use the patented technology, a covenant not to sue, a release of the party from certain claims, the dismissal of any pending litigation and other terms. Our strategy has been developed with the expectation that it will result in a long-term, diversified revenue stream for the Company. As of September 30, 2015, we owned 369 U.S. and foreign patents and patent rights and ten patent applications. As used in this report, the terms “we”, “us”, “our”, the “Company”, “Marathon Patent Group, Inc.” “Marathon”, and “MARA” mean Marathon Patent Group, Inc. and its subsidiaries, unless otherwise indicated. Our principal office is located at 11100 Santa Monica Blvd., Suite 380, Los Angeles, CA 90225. Our telephone number is (703) 232-1701. We were incorporated in the State of Nevada on February 23, 2010 under the name “Verve Ventures, Inc.” On December 7, 2011, we changed our name to “American Strategic Minerals Corporation” and were engaged in exploration and potential development of uranium and vanadium minerals business. During June 2012, we discontinued our minerals business and began to invest in real estate properties in Southern California. In November 2012, we discontinued our real estate business. On December 7, 2011, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of the State of Nevada in order to change its name to “American Strategic Minerals Corporation” from “Verve Ventures, Inc.”, and increase the Company’s authorized capital to 200,000,000 shares of common stock, par value $0.0001 per share, and 50,000,000 shares of preferred stock, par value $0.0001 per share. During June 2012, the Company decided to discontinue its exploration and potential development of uranium and vanadium minerals business. On August 1, 2012, the shareholders holding a majority of the Company’s voting capital voted in favor of (i) changing the name of the Company to “Fidelity Property Group, Inc.” and (ii) the adoption the 2012 Equity Incentive Plan and reserving 10,000,000 shares of common stock for issuance thereunder (the “2012 Plan”). The board of directors of the Company (the “Board of Directors”) approved the name change and the adoption of the 2012 Plan on August 1, 2012. The Company did not file an amendment to its Articles of Incorporation with the Secretary of State of Nevada and subsequently abandoned the decision to adopt the “Fidelity Property Group, Inc.” name and discontinue its real estate business. On October 1, 2012, the shareholders holding a majority of the Company’s voting capital had voted and authorized the Company to (i) change the name of the Company to Marathon Patent Group, Inc. (the “Name Change”) and (ii) effectuate a reverse stock split of the Company’s common stock by a ratio of 3-for-2 (the “Reverse Split”) within one year from the date of approval of the stockholders of the Company. The Board of Directors approved the Name Change and the Reverse Split on October 1, 2012. The Board of Directors determined the name “Marathon Patent Group, Inc.” better reflected the long-term strategy in exploring other opportunities and the identity of the Company going forward. On February 15, 2013, the Company filed the Certificate of Amendment with the Secretary of State of the State of Nevada in order to effectuate the Name Change. On May 31, 2013, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-five and not more than one-for-fifteen at any time prior to April 30, 2014, with such ratio to be determined by the Company’s Board of Directors, in its sole discretion. On June 24, 2013, the reverse stock split ratio of one (1) for thirteen (13) basis was approved by the Board of Directors. On July 18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for thirteen (13) basis. All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split. On September 16, 2014, the Board of Directors of the Company approved and adopted, subject to shareholder approval on or prior to September 16, 2015, the Company’s 2014 Equity Incentive Plan. The Company’s 2014 Equity Incentive Plan was approved by the shareholders of the Company at the annual meeting held on July 31, 2015. On November 19, 2014, the Board of Directors of the Company declared a stock dividend pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 shall receive one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders. All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the stock dividend.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The unaudited consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and present the consolidated financial statements of the Company and its wholly-owned subsidiaries. In the preparation of consolidated financial statements of the Company, all intercompany transactions and balances were eliminated. All adjustments (consisting of normal recurring items) necessary to present fairly the Company’s consolidated financial position as of September 30, 2015, and the results of operations and cash flows for the three and nine months ended September 30, 2015 have been included. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the full year. Other than where noted, the accounting policies and procedures employed in the preparation of these consolidated financial statements have been derived from the audited financial statements of the Company for the year ended December 31, 2014, which are contained in Form 10-K as filed with the Securities and Exchange Commission (“SEC”) on March 26, 2015. The consolidated balance sheet as of December 31, 2014 was derived from those financial statements. Cash The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. The Company’s accounts at this institution are insured up to $250,000 by the Federal Deposit Insurance Corporation (“FDIC”). As of September 30, 2015, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits. Pursuant to the agreement with Fortress, the Company has agreed to a minimum cash covenant in the amount of $1,000,000. Use of Estimates and Assumptions The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting. Accounts Receivable The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote. At September 30, 2015 and December 31, 2014, the allowance for bad debt was $0 and $0, respectively. Accounts receivable-net at September 30, 2015 and December 31, 2014, amounted to $2,326,717 and $216,997, respectively. As of September 30, 2015, accounts receivable related to two licenses accounted for approximately 81% of the Company’s total accounts receivable, accounts receivable related to recurring royalties represented approximately 3% of total accounts receivable and the Company had a receivable from an indemnification claim to be paid by the seller of a portfolio purchased by the Company in the amount of $375,750 or 16% of total accounts receivable. As of December 31, 2014, 86% of total accounts receivable were associated with outstanding recurring royalties and 14% were associated with one outstanding license payment. Concentration of Revenue and Geographic Area Patent license revenue from enforcement activities is from either the United States or Germany. Revenue attributable to the United States involves US patents; revenue attributable to Germany is based on the enforcement of German patents and in the event that the Company enters into a worldwide license, the revenue is allocated between the two. The Company does not currently have enforcement actions in any other countries. Revenues from five licenses accounted for approximately 87% of the Company’s operating revenues for the three months ended September 30, 2015 and revenue from five licenses accounting for 100% of the revenue for the three months ended September 30, 2014. For the Three Months Ended September 30, 2015 For the Three Months Ended September 30, 2014 Licensor License Amount % of Revenue Licensor License Amount % of Revenue Orthophoenix, LLC $ Clouding Corp. $ IP Liquidity Ventures, LLC Selene Communications Technologies, LLC $ TLI Communications LLc / TLI Communications GmbH $ Selene Communications Technologies, LLC $ Clouding Corp. $ Cyberfone Systems LLC $ Signal IP, Inc. $ Cyberfone Systems LLC $ Total Total While the Company has a growing portfolio of patents, the Company has historically received a significant portion of its revenue and expects that a significant portion of its future revenues will be based on one-time grants of similar non-recurring, non-exclusive, non-assignable licenses to a relatively small number of entities and their affiliates. Further, with the expected small number of firms with which the Company enters into license agreements, and the amount and timing of such license agreements, the Company also expects that its revenues may be highly variable from one period to the next. Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 605, “Revenue Recognition”. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. The Company considers its licensing and enforcement activities as one unit of accounting under ASC 605-25, “Multiple-Element Arrangements” as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use, and the release. Also, due to the fact that the settlement element and license element for past and future use are the major central business, the Company does not present these two elements as different revenue streams in its statements of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. The Company derived approximately 97% and 100% of its revenues for the three months ended September 30, 2015 and September 30, 2014, respectively, and 94% and 100% of its revenues for the nine months ended September 30, 2015 and September 30, 2014, respectively, from the one-time issuance of non-recurring, non-exclusive, non-assignable licenses for certain of the Company’s patents, with the balance comprised of recurring royalties and Opus subscription fees. The Company’s subsidiaries entered into eleven license agreements during the three months ended September 30, 2015. Cost of Revenue Cost of revenue mainly includes expenses incurred in connection with the Company’s patent enforcement activities, such as legal fees, consulting costs, patent maintenance, royalty fees for acquired patents and other related expenses. Cost of revenue does not include patent amortization expenses, which are included as a separate line item in operating expenses and cost of revenue also does not include expenses related to product development, integration or support, as these are included in general and administrative expenses. Prepaid Expenses, Bonds Posted and Other Current Assets Prepaid expenses and other current assets of $114,953 and $438,391 at September 30, 2015 and December 31, 2014, respectively, consist primarily of costs paid for future services and the unamortized portion of a convertible loan fee, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements. In addition, the Company had outstanding litigation bonds in the amount of $1,794,226 and $1,946,196 at September 30, 2015 and December 31, 2014, respectively. These bonds were entered into in Germany after the first instance of litigation of some of the Company’s patents in German courts and the difference in the balance of the litigation bonds at December 31, 2014 versus September 30, 2015 is attributable solely to currency translation. Fair Value of Financial Instruments The Company adopted FASB ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing US GAAP that require the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The carrying amounts reported in the consolidated balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company. Clouding IP earn out liability was determined as a Level 3 liability, which requires fair assessment of fair value at each period end by using discounted cash flow as valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of September 30, 2015, the Company determined Clouding IP earnout liability as $327,757 for current portion and $6,222,895 as long-term portion, which resulted in gain from exchange in fair value adjustment of $597,047 and $2,901,348 for three and nine months ended September 30, 2015, respectively. Further, the periodic reassessment resulted in non-routine impairment of Clouding patent intangible assets of $0 and $766,498 for the three and nine months ended September 30, 2015. Accounting for Acquisitions In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses. With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 – Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis. The Company performs such analysis with respect to each material acquisition within the consolidated group of entities. Income Taxes The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized. The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is highly certain that some positions taken would be situated upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits. The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For a tax position considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the previous year’s tax returns. After review of the prior year financial statements and the results of operations through September 30, 2015, the Company has recorded a deferred tax asset in the amount of $10,529,693, from which the Company expects to realize benefits in the future, and a deferred tax liability of $1,056,406. The Company files U.S. and state income tax returns with varying statutes of limitations. The 2011 through 2014 tax years generally remain subject to examination by federal and state tax authorities. Basic and Diluted Net Earnings (Loss) per Share Net earnings (loss) per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (“ASC 260”). Basic earnings (loss) per share is computed by dividing net earnings (loss) by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net earnings (loss) per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 2,886,392 shares of common stock and warrants to purchase 2,021,308 shares of common stock outstanding at September 30, 2015, which were excluded from the computation of diluted shares outstanding, as they would have had an anti-dilutive impact on the Company’s net loss. The following table sets forth the computation of basic and diluted loss per share: For the Three Months Ended September 30, 2015 For the Three Months Ended September 30, 2014 For the Nine Months Ended September 30, 2015 For the Nine Months Ended Septemer 30, 2014 Net income (loss) $ $ Denominator Weighted Average Common Shares - Basic Weighted Average Common Shares - Diluted Earnings (Loss) per common share: Income (Loss) - Basic $ $ $ $ Income (Loss) - Diluted $ $ $ $ Intangible Assets Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company performs the annual testing for impairment of intangible assets at the reporting unit level during the quarter ended September 30. The Company did not record any impairment charges to its intangible assets during the three months ended September 30, 2015 and 2014 and recorded impairment charges of $766,498 and $0 for the nine months ended September 30, 2015 and 2014, respectively. Goodwill Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: 1. Significant underperformance relative to expected historical or projected future operating results; 2. Significant changes in the manner of use of the acquired assets or the strategy for the overall business; 3. Significant negative industry or economic trends; and 4. Significant reduction or exhaustion of the potential licenses of the patents which gave rise to the goodwill. When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired and the Company is not required to perform further testing. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30. The Company did not record any impairment charges to its goodwill during the three months ended September 30, 2015, whereas the Company recorded an impairment charge in the amount of $2,144,488 to the goodwill associated with CyberFone for the three months ended September 30, 2014 and recorded impairment charges to goodwill in the amount of $0 and $2,144,488 for the nine months ended September 30, 2015 and 2014, respectively. Impairment of Long-lived Assets The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 “Property, Plant and Equipment”. The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The Company did not record any impairment charges on its long-lived assets during the three and nine months ended September 30, 2015 and 2014. Stock-based Compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. As stock-based compensation expense is recognized based on awards expected to vest , forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the three and nine months ended September 30, 2015, the expected forfeiture rate was 11.66% and 11.66%, respectively, which resulted in an expense of $8,423 and $16,004, respectively, recognized in the Company’s compensation expenses. There were no forfeitures for the three and nine months ended September 30, 2014. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters. Reclassification Certain prior year reported amounts have been reclassified to conform to the current year presentation. The reclassification did not have an impact on previously issued net income (loss) or Total Shareholders’ Equity. Recent Accounting Pronouncements In September 2015, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, or ASU 2015-16. This amendment requires the acquirer in a business combination to recognize in the reporting period in which adjustment amounts are determined, any adjustments to provisional amounts that are identified during the measurement period, calculated as if the accounting had been completed at the acquisition date. Prior to the issuance of ASU 2015-16, an acquirer was required to restate prior period financial statements as of the acquisition date for adjustments to provisional amounts. The new standard for an annual reporting period beginning after December 15, 2017 with an earlier effective application is permitted only as of annual reporting periods beginning after December 15, 2016. The new guidance is not expected to have significant impact on the Company’s consolidated financial statements, In April 2015, the FASB issued ASU 2015-05, Intangibles-Goodwill and Other – Internal-Use Software; Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement . Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer’s accounting for fees paid in a cloud computing arrangement. Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The ASU does not change the accounting for service contracts. The new standard is effective for us on January 1, 2016 with early adoption permitted. We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements. In April 2015, the FASB issued new guidance on the presentation of debt issuance costs (ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs) , effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years and should be applied retrospectively to all periods presented. Early adoption of the new guidance is permitted for financial statements that have not been previously issued. The new guidance will require that debt issuance costs be presented in the balance sheet as a direct deduction from the related debt liability rather than as an asset, consistent with debt discounts. The Company adopted ASU 2015-03 and as such, the debt issuance costs for Fortress note was presented in the balance sheet as direct deduction from the related debt liability. In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. This standard update provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016. The new guidance is not expected to have significant impact on the Company’s consolidated financial statements. In May 2014, the Financial Accountings Standards Board ( “FASB” ) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers , or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and shall take effective on January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method and the early application of the standard is not permitted. The Company is presently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.

ACQUISITIONS

ACQUISITIONS	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
NOTE 3 - ACQUISITIONS	NOTE 3 – ACQUISITIONS CyberFone On April 22, 2013, CyberFone Acquisition Corp., a Texas corporation and newly formed wholly owned subsidiary of the Company (“Acquisition Corp”) entered into a merger agreement (“CyberFone Merger Agreement”) with CyberFone Systems, LLC (“CyberFone”), TechDev Holdings, LLC (“TechDev”) and The Spangenberg Family Foundation for the Benefit of Children’s Healthcare and Education (“SFF” and together with TechDev, “CyberFone Sellers”). TechDev and SFF owned 100% of the membership interests of CyberFone Systems. CyberFone owns a foundational patent portfolio that includes claims that provide specific transactional data processing, telecommunications, network and database inventions, including financial transactions. The portfolio, which has a large and established licensing base, consists of ten United States patents and 27 foreign patents and one patent pending. The patent rights that cover digital communications and data transaction processing are foundational to certain applications in the wireless, telecommunications, financial and other industries. IP Navigation Group LLC (“IP Nav”), a Company founded by Erich Spangenberg and associated with the CyberFone Sellers will continue to support and manage the portfolio of patents and retain a contingent participation interest in all recoveries. IP Nav provides patent monetization and support services under an existing agreement with CyberFone. Pursuant to the terms of the CyberFone Merger Agreement, CyberFone merged with and into Acquisition Corp. with CyberFone surviving the merger as the wholly owned subsidiary of the Company. The Company (i) issued 461,538 post-split (6,000,000 pre-split) shares of common stock to the CyberFone Sellers, (ii) paid the CyberFone Sellers $500,000 cash and (iii) issued a $500,000 promissory note to TechDev. The Company valued these common shares at the fair market value on the date of grant at $4.94 post-split ($0.38 pre-split) per share or $2,280,000. The note was non-interest bearing and was due on June 22, 2013, subject to acceleration in the event of default. The Company may prepay the note at any time without premium or penalty. On June 21, 2013, the Company paid $500,000 to TechDev in satisfaction of the note. The transaction resulted in a business combination and caused CyberFone to become a wholly-owned subsidiary of the Company. In addition to the payments described above, within 30 days following the end of each calendar quarter (commencing with the first full calendar quarter following the calendar quarter in which CyberFone recovers $4 million from licensing or enforcement activities related to the patents), CyberFone will be required to pay out a certain percentage of such recoveries. The Company accounted for the acquisition utilizing the purchase method of accounting in accordance with ASC 805 “Business Combinations”. The Company is the acquirer for accounting purposes and CyberFone is the acquired company. Accordingly, the Company applied push–down accounting and adjusted to fair value all of the assets and liabilities directly on the financial statements of the Company subsidiary. The net purchase price paid by the Company was allocated to assets acquired and liabilities assumed on the records of the Company as follows: Intangible assets $ Goodwill Net purchase price $ Per the disclosure set forth above, the Company determined at September 30, 2014 that the goodwill was impaired and an impairment loss in the amount of $2,144,488 was charged to the consolidated statements of operations. Dynamic Advances, IP Liquidity and Sarif Biomedical On May 2, 2014, the Company completed the acquisition of certain ownership rights (the “Acquired Intellectual Property”) from TechDev, Granicus IP, LLC (“Granicus”) and SFF pursuant to the terms of three purchase agreements between: (i) the Company, TechDev, SFF and DA Acquisition LLC, a newly formed Texas limited liability company and wholly-owned subsidiary of the Company; (ii) the Company, Granicus, SFF and IP Liquidity Ventures Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company; and (iii) the Company, TechDev, SFF and Sarif Biomedical Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company (the “DA Agreement,” the “IP Liquidity Agreement” and the “Sarif Agreement,” respectively and the collective transactions, the “Acquisitions”). Dynamic Advances Pursuant to the DA Agreement, the Company acquired 100% of the limited liability company membership interests of Dynamic Advances, LLC, a Texas limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment due on or before September 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 195,500 shares of the Company’s Series B Convertible Preferred Stock. Under the terms of the DA Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below. Dynamic Advances, LLC holds exclusive license to monetize certain patents owned by a third party. On May 2, 2014, the Company issued TechDev and SFF a promissory note in order to evidence the second cash payment due under the terms of the DA Agreement in the amount of $2,375,000 due on or before September 30, 2014, with such amount due under the terms of the promissory note being subject to increase to $2,850,000 if the Company’s payment pursuant to the terms of the DA Agreement are not made on or before June 30, 2014. The promissory note matured on September 30, 2014; effective September 30, 2014, TechDev and SFF extended the maturity to March 31, 2015 in return for a payment of $249,375, payable within thirty days. The payment for this extension of the maturity date was made on October 10, 2014 and the promissory note was repaid on April 1, 2015. The promissory note does not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June 30, 2014, the Company included in the consideration paid for Dynamic Advances the promissory note balance of $2,850,000. Further, the Company had the Series B Convertible Preferred Stock valued by a third party firm that determined, based on the rights and privileges of the Series B Convertible Preferred Stock, that it was on par with the value of the Company’s Common Stock. The total amount of consideration paid by the Company for Dynamic Advances, including capitalized costs associated with the purchase, was $6,653,078. After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets. Further, as there are no assumed licensees or historical revenues, the Company is not certain that it will be able to obtain access to customers pursuant to ASC 805-10-55-7. IP Liquidity Pursuant to the IP Liquidity Agreement, the Company acquired 100% of the limited liability company membership interests of IP Liquidity Ventures, LLC, a Delaware limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment due on or before September 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 195,500 shares of the Company’s Series B Convertible Preferred Stock. Under the terms of the IP Liquidity Agreement, Granicus and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below. IP Liquidity Ventures, LLC holds contract rights to the proceeds from the monetization of certain patents owned by a number of third parties. On May 2, 2014, the Company issued Granicus and SFF a promissory note in order to evidence the second cash payment due under the terms of the IP Liquidity Agreement in the amount of $2,375,000 due on or before September 30, 2014, with such amount due under the terms of the promissory note being subject to increase to $2,850,000 if the Company’s payment pursuant to the terms of the IP Liquidity Agreement are not made on or before June 30, 2014. The promissory note matured on September 30, 2014; effective September 30, 2014, Granicus and SFF extended the maturity to March 31, 2015 in return for a payment of $249,375, payable within thirty days. The payment for this extension of the maturity date was made on October 10, 2014 and the promissory note was repaid on April 1, 2015. The promissory note does not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June 30, 2014, the Company included in the consideration paid for IP Liquidity the promissory note balance of $2,850,000. Further, the Company had the Series B Convertible Preferred Stock valued by a third party firm that determined, based on the rights and privileges of the Series B Convertible Preferred Stock that it was on par with the value of the Company’s Common Stock. The total amount of consideration paid by the Company for IP Liquidity, including capitalized costs associated with the purchase, was $6,653,078. After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets. Further, as there are no assumed licensees or historical revenues, the Company is not certain that it will be able to obtain access to customers pursuant to ASC 805-10-55-7. Sarif Biomedical Pursuant to the Sarif Agreement, the Company acquired 100% of the limited liability company membership interests of Sarif Biomedical, LLC, a Delaware limited liability company, in consideration for two cash payments of $250,000, one payment due at closing and the other payment due on or before September 30, 2014, with such second payment being subject to increase to $300,000 if not made on or before June 30, 2014. Under the terms of the Sarif Agreement, TechDev is entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below. Sarif Biomedical, LLC holds ownership rights to certain patents. On May 2, 2014, the Company issued TechDev a promissory note in order to evidence the second cash payment due under the terms of the Sarif Agreement in the amount of $250,000 due on or before September 30, 2014, with such amount due under the terms of the promissory note being subject to increase to $300,000 if the Company’s payment pursuant to the terms of the Sarif Agreement are not made on or before September 30, 2014. The promissory note matured on September 30, 2014; effective September 30, 2014, TechDev extended the maturity to March 31, 2015 in return for a payment of $26,250, payable within thirty days. The payment for this extension of the maturity date was made on October 10, 2014 and the promissory note was repaid on April 1, 2015. The promissory note does not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June 30, 2014, the Company included in the consideration paid for Dynamic Advances the higher principal amount of the promissory note. The total amount of consideration paid by the Company for Sarif Biomedical, including capitalized costs associated with the purchase, was $552,024. After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets. Further, as there are no assumed licensees or historical revenues, the Company is not certain that it will be able to obtain access to customers pursuant to ASC 805-10-55-7. Dynamic Advances, IP Liquidity and Sarif Biomedical Pursuant to the Pay Proceeds Agreement, the Company may pay the sellers a percentage of the net recoveries (gross revenues minus certain defined expenses) that the Company makes with respect to the assets held by the entities that the Company acquired pursuant to the DA Agreement, the IP Liquidity Agreement and the Sarif Agreement (the “IP Assets”). Under the terms of the Pay Proceeds Agreement, if the Company recovers $10,000,000 or less with regard to the IP Assets, then nothing is due to the sellers; if the Company recovers between $10,000,000 and $40,000,000 with regard to the IP Assets, then the Company shall pay 40% of the net proceeds of such recoveries to the sellers; and if the Company recovers over $40,000,000 with regard to the IP Assets, the Company shall pay 50% of the net proceeds of such recoveries to the sellers. In no event will the total payments made by the Company under the Pay Proceeds Agreement exceed $250,000,000. Pursuant to a Registration Rights Agreement with the sellers (the “Acquisition Registration Rights Agreement”), the Company agreed to file a “resale” registration statement with the SEC covering at least 10% of the registrable shares of the Company’s Series B Convertible Preferred Stock issued to the sellers under the terms of the DA Agreement and the IP Liquidity Agreement, at any time on or after November 2, 2014 upon receipt of a written demand from the sellers which describes the amount and type of securities to be included in the registration and the intended method of distribution thereof. The Company shall not be required to file more than three such registration statements not more than 60 days after the receipt of each such written demand from the sellers. TechDev and Mr. Erich Spangenberg (the founder of IP Nav) and his spouse Audrey Spangenberg have jointly filed a Schedule 13G and are deemed to be affiliates of the Company. Selene Communication Technologies On June 17, 2014, Selene Communication Technologies Acquisition LLC (“Acquisition LLC”), a Delaware limited liability company and newly formed wholly owned subsidiary of the Company, entered into a merger agreement with Selene Communication Technologies, LLC (“Selene”). Selene owns a patent portfolio consisting of three United States patents in the field of search and network intrusion that relate to tools for intelligent searches applied to data management systems as well as global information networks such as the internet. IP Nav will continue to support and manage the portfolio of patents and retain a contingent participation interest in all recoveries. IP Nav provides patent monetization and support services under an existing agreement with Selene. Pursuant to the terms of the Selene Interests Sale Agreement, Selene merged with and into Acquisition LLC with Selene surviving the merger as the wholly owned subsidiary of the Company. The Company (i) issued 100,000 shares of common stock to the Selene Sellers and (ii) paid the Selene Sellers $50,000 cash. The Company valued these common shares at the fair market value on the date of grant at $9.80 per share or $980,000. The transaction resulted in a business combination and caused Selene to become a wholly-owned subsidiary of the Company. The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations” in which the Company is the acquirer for accounting purposes and Selene is the acquired company. The fair value of the assets purchased, and the net purchase price paid by the Company was allocated to assets acquired and liabilities assumed on the records of the Company as follows: Intangible assets $ Net working capital Goodwill Net purchase price $ Clouding Corp. On August 29, 2014, the Company entered into a patent purchase agreement (the “Clouding Agreement”) between Clouding Corp., a Delaware corporation and a wholly owned subsidiary of the Company (“Clouding”) and Clouding IP, LLC, a Delaware limited liability company (“Clouding IP”), pursuant to which Clouding acquired a portfolio of patents from Clouding IP. Clouding owns patents related to network and data management technology. The Company paid Clouding IP (i) $1.4 million in cash, (ii) $1.0 million in the form of a promissory note issued by the Company that matures on October 31, 2014, (iii) 25,000 shares of its restricted common stock valued at $281,000 and (iv) fifty percent (50%) of the net recoveries (gross revenues minus certain defined expenses) in excess of $4.0 million in net revenues that the Company makes with respect to the patents purchased from Clouding IP. The Company valued the Common Stock at the fair market value on the date of the Interests Sale Agreement at $11.24 per share or $281,000 and the promissory note was paid in full prior to October 31, 2014. The revenue share under item (iv) above was booked as an earn out liability on the balance sheet in accordance with the appraisal of the consideration and intangible value. The Company has paid $2,148,000 from the acquisition date to September 30, 2015 to the sellers pursuant to the earn out liability, based on license agreements entered in the third quarter of 2014. No further amount is owed until the Company generates additional revenue, if any, from the Clouding patents. The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations”. The fair value of the assets purchased, and the net purchase price paid by the Company was allocated to assets acquired and liabilities assumed on the records of the Company as follows: Intangible assets $ Goodwill Net purchase price $ Total consideration paid of the following: Cash $ Promissory Note Common Stock Earn Out Liability Net purchase price $ Historical financial statements of Clouding IP and the pro forma condensed combined consolidated financial statements (both carve-out of certain operations of Clouding IP) can be found on the Form 8-K/A filed with the SEC on November 12, 2014. The unaudited pro forma condensed combined consolidated financial statements are not necessarily indicative of the results that actually would have been attained if the merger had been in effect on the dates indicated or which may be attained in the future. Such statements should be read in conjunction with the historical financial statements of the Company. Clouding IP earn out liability was determined as a Level 3 liability, which requires fair assessment of fair value at each period end by using discounted cash flow as valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of September 30, 2015, the Company determined Clouding IP earnout liability as $327,757 for current portion and $6,222,895 as long-term portion, which resulted in gain from exchange in fair value adjustment of $597,047 and $2,901,348 for three and nine months ended September 30, 2015, respectively. Further, the periodic reassessment resulted in non-routine impairment of Clouding patent intangible assets of $0 and $766,498 for the three and nine months ended September 30, 2015. TLI Communications LLC On September 19, 2014, TLI Acquisition Corp (“TLIA”), a Virginia corporation and newly formed wholly owned subsidiary of the Company, entered into an interest sale agreement to purchase 100% of the membership interests of TLI Communications LLC (“TLIC”), a Delaware limited liability company. TLIC owns a patent in the telecommunications field. Pursuant to the terms of the TLIC Interests Sale Agreement, TLIC merged with and into TLIA with TLIC surviving the merger as the wholly owned subsidiary of the Company. The Company (i) agreed to issue 60,000 shares of Common Stock to the sellers of TLIC (“TLIC Sellers”), (ii) paid the TLIC Sellers $350,000 cash and (iii) agreed to pay the TLIC Sellers a fifty percent (50%) of the net recoveries (gross revenues minus certain defined expenses and the cash portion of the acquisition consideration) that the Company makes with respect to the patent purchased pursuant to the acquisition of TLIC. The Company valued the Common Stock at the fair market value on the date of the Interests Sale Agreement at $13.63 per share or $818,000. The cash portion of the consideration was outstanding at September 30, 2014 and was subsequently paid in October. The transaction resulted in a business combination and caused TIC to become a wholly-owned subsidiary of the Company. The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations”. The Company is the acquirer for accounting purposes and TLIC is the acquired company. The fair value of the assets purchased, and the net purchase price paid by the Company was allocated to assets acquired and liabilities assumed on the records of the Company as follows: Intangible assets $ Goodwill Net purchase price $ Medtech Entities On October 13, 2014, Medtech Group Acquisition Corp (“Medtech Corp.”), a Texas corporation and newly formed wholly owned subsidiary of the Company, entered into an interest sale agreement to purchase 100% of the equity or membership interests of OrthoPhoenix, LLC (“OrthoPhoenix”), a Delaware limited liability company, TLIF, LLC (“TLIF”) and MedTech Development Deutschland GmbH (“MedTech GmbH” and along with OrthoPhoenix and TLIF, the “Medtech Entities”) from MedTech Development, LLC (“MedTech Development”). The Medtech Entities own patents in the medical technology field. Pursuant to the terms of the Interest Sale Agreement between MedTech Development, Medtech Corp. and the Medtech Entities, the Company (i) paid MedTech Development $1,000,000 cash and (ii) issue a Promissory Note to MedTech Development in the amount of $9,000,000 and (iii) assumed existing debt payable to Medtronics, Inc. The assumed debt payable to Medtronics was renegotiated, as a result of which, the outstanding amount was $6.25 million prior to any repayment by the Company. The debt is due in installments through July 20, 2015; in the event that the Company paid the total amount due by June 30, 2015, the Company would have received a reduction in the remaining principal owed by the Company in the amount of $750,000. Since the Company expected to make the payment by that time when it entered into the agreement, the Company took a discount to the principal amount during the fourth quarter of 2014 when it made the acquisition. However, since the Company did not actually make the payment of the final principal amount by June 30, 2015, the Company reversed the earlier discount as of June 30, 2015. The transaction resulted in a business combination and caused the Medtech Entities to become wholly-owned subsidiaries of the Company. The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations”. The Company is the acquirer for accounting purposes and TLIC is the acquired company. The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows: Intangible assets $ Goodwill Net purchase price $ Historical financial statements of the Medtech Entities and the pro forma condensed combined consolidated financial statements can be found on the Form 8-K/A filed with the SEC on December 24, 2014. The unaudited pro forma condensed combined consolidated financial statements are not necessarily indicative of the results that actually would have been attained if the merger had been in effect on the dates indicated or which may be attained in the future. Such statements should be read in conjunction with the historical financial statements of the Company. On July 16, 2015, the Company entered into a forbearance agreement (the “Agreement”) with MedTech Development, the holder of a Promissory Note issued by the Company, dated October 10, 2014. Pursuant to the Agreement, the term of the Note was extended to October 1, 2015 and the Note began accruing interest starting from May 13, 2015. In addition, the Company agreed to make certain mandatory prepayments under certain circumstances and issue to MedTech Development 200,000 shares of restricted common stock of the Company. In accordance with ASC 470-50, the Company recorded this agreement as debt extinguishment and $654,000 was recorded as loss on debt extinguishment for the three and nine months ended September 30, 2015. Bridgestone Americas Tire Operations, LLC (“BATO”) On April 23, 2015, IP Liquidity entered into a Patent Purchase Agreement (“BATO PPA”), as amended, whereby IP Liquidity purchased 43 patents from Bridgestone Americas Tire Operations LLC (“BATO”). Pursuant to the terms of the BATO PPA, the Company agreed to pay BATO (i) $3.5 million in two increments shortly after the execution of the document and (ii) an additional $6.5 million in the event that the Company funds the German court bond requirement to put an injunction in place. The Company has not made the first payment to BATO pending further potential amendments to the BATO PPA. The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 “Business Combinations”. The Company engaged a third party valuation firm to determine the fair value of the assets purchased, which determined that the fair value of the assets was in excess of the purchase consideration, so the Company booked the assets at the purchase consideration of $10 million. Uniloc Luxembourg SA On August 14, 2015, Marathon Patent Group, Inc., a Nevada corporation (“Marathon”), entered into a Business Combination Agreement (the “Business Combination Agreement”) with Marathon Group SA, a Luxembourg société anonyme (“Holdco”) and Uniloc Luxembourg SA, a Luxembourg société anonyme (“Uniloc”), and Uniloc Corporation Pty. Limited, an Australian corporation (“Uniloc Australia”). Subject to the satisfaction or waiver of the conditions in the Business Combination Agreement and on the terms in the Business Combination Agreement, at the closing of the transactions contemplated by the Business Combination Agreement (the “Closing”): · All of Marathon’s outstanding shares, warrants and options will be exchanged, for approximately 45% of Holdco’s fully-diluted capitalization, resulting in Marathon becoming a wholly-owned subsidiary of Holdco; and · Uniloc will transfer substantially all of its assets and liabilities to a new wholly-owned Luxembourg subsidiary (“New Uniloc”). Following that transfer, Uniloc will merge with and into Holdco, resulting in New Uniloc becoming a wholly-owned subsidiary of Holdco. · Holdco has the option to acquire from Uniloc Australia its Uniloc USA Holdings subsidiary. As consideration for these transactions, Holdco will issue its ordinary shares representing approximately 55% of Holdco’s fully diluted capitalization. The Closing is subject to customary conditions, including: · the approval of the Business Combination Agreement by Marathon stockholders; · the approval of the Business Combination by the Uniloc shareholders; · receipt of necessary third party consents, including, among others, from affiliates of Fortress Investment Group, which is a lender to both Marathon and Uniloc; · the truth and accuracy of the other party’s representations and warranties in the Business Combination Agreement; · the non-occurrence of a Material Adverse Effect (as defined in the Business Combination Agreement) with respect to the other party; · listing of the Holdco ordinary shares on NASDAQ; · new offers of employment being made to senior management of Marathon and Uniloc; and · the performance by the other party of all of its obligations and compliance with all of its covenants under the Business Combination Agreement in all material respects. The Business Combination Agreement contains customary representations, warranties and covenants by each of Marathon and Uniloc for a transaction of this nature. Marathon and Uniloc each have agreed, among other things, subject to the exceptions in the Business Combination Agreement, prior to termination of the agreement, not to directly or indirectly: · initiate, solicit, or knowingly take any action to facilitate or encourage, or participate or engage in any negotiations, inquiries or discussions with respect to any Acquisition Proposal (as defined in the Business Combination Agreement), · in connection with any potential Acquisition Proposal, disclose or furnish any nonpublic information or data to any Person concerning Marathon’s business or properties or afford any Person other than Uniloc or its Representatives access to its properties, books, or records, except as required by Law or pursuant to a governmental request for information, · enter into or execute, or propose to enter into or execute, any agreement relating to an Acquisition Proposal, or · approve, endorse, recommend or make or authorize any public statement, recommendation, or solicitation in support of any Acquisition Proposal. Marathon will, and will direct its Representatives to, cease immediately and cause to be terminated all discussions and negotiations that commenced prior to the date of this Agreement regarding any proposal that constitutes, or could reasonably be expected to lead to, an Acquisition Proposal. In addition, each of the parties agreed to use, subject to the terms and conditions of the Business Combination Agreement, commercially reasonable efforts to cause the transactions to be consummated as promptly as practicable. The Business Combination Agreement also requires each of Marathon and Uniloc to call and hold shareholders’ meetings, as expeditiously as possible, and requires the board of directors of each of Marathon and Uniloc to recommend approval of the transactions. Holdco will prepare and file with the United States Securities and Exchange Commission a registration statement on Form S-4 in connection with the Marathon vote and registration of the Ordinary Shares. The Business Combination Agreement may be terminated by mutual written consent of the parties. Among other termination rights, the Business Combination Agreement also contains termination rights giving either party a termination right if: · the transactions have not been consummated by March 1, 2016, but this date may be extended to May 31, 2016 if regulatory approvals are not timely obtained; · the Uniloc and/or Marathon shareholder approvals are not obtained; · the other party breaches its representations and covenants and such breach would result in the closing conditions not being satisfied; and · each of Uniloc and Marathon has the right to terminate the Business Combination Agreement to accept a superior proposal on the express conditions described in the Business Combination Agreement, including, among other things, no violation of the restrictions on soliciting an alternative proposal. In connection with the transactions described, on August 14, 2015, certain shareholders of each of Marathon and Uniloc entered into Support Agreements (the “Support Agreement”) under which they agreed to vote their respective shares of Marathon and Uniloc in favor of the approval of the Business Combination Agreement in certain circumstances. The Closing is expected to occur during the first quarter of 2016.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
NOTE 4 - INTANGIBLE ASSETS	NOTE 4 – INTANGIBLE ASSETS Intangible assets of the Company, including adjustments for currency translation adjustments, consisted of the following: September 30, 2015 December 31, 2014 Intangible Assets $ $ Accumulated Amortization & Impairment Intangible assets, net $ $ Intangible assets are comprised of patents with estimated useful lives between approximately 1 to 15 years. Once placed in service, the Company will amortize the costs of intangible assets over their estimated useful lives on a straight-line basis. Costs incurred to acquire patents, including legal costs, are also capitalized as long-lived assets and amortized on a straight-line basis with the associated patent. Amortization of patents is included in operating expenses as reflected in the accompanying consolidated statements of operations. As of September 30, 2015 and December 31, 2014, management concluded that there was no impairment to the intangible assets. Patent amortization expense for the three and nine months ended September 30, 2015 was $2,884,269 and $8,511,730, respectively and patent amortization expense for the three and nine months ended September 30, 2014 was $1,480,311 and $2,872,638, respectively, net of foreign currency translation adjustments. Gross future amortization of intangible assets, not incorporating foreign currency translation adjustments, is as follows: 2015 $ 2016 2017 2018 2019 2020 and thereafter Total $ The Company made the following patent purchases: - In April 2013, the Company through its subsidiary, Relay IP, Inc. acquired a US patent for $350,000; - In April 2013, the Company acquired 10 US patents, 27 foreign patents and 1 patent pending from CyberFone Systems valued at $1,135,512; - In June 2013, in connection with the closing of a licensing agreement with Siemens Technology, we acquired a patent portfolio from that company valued at $1,000,000; - In September 2013, the Company acquired 14 US patents for a total purchase price of $1,100,000; - In November 2013, the Company acquired four patents for 150,000 shares of the Company’s Common Stock, which the Company valued at $718,500 based on the fair market value of the stock issued; - In December 2013, the Company acquired certain patents from Delphi Technologies, Inc. for $1,700,000 pursuant to a Patent Purchase Agreement entered into on October 31, 2013 and Amended on December 16, 2013; - In December 2013, in connection with a licensing agreement with Zhone, the Company acquired a portfolio of patents from Zhone; - In December 2013, in connection with a settlement and license agreement, we agreed to settle and release another defendant for past and future use of our patents, whereby the defendant agreed to assign and transfer 2 U.S. patents and rights to the Company; - In May 2014, we acquired ownership rights of Dynamic Advances, LLC, a Texas limited liability company, IP Liquidity Ventures, LLC, a Delaware limited liability company, and Sarif Biomedical, LLC, a Delaware limited liability company, all of which hold patent portfolios or contract rights to the revenue generated from the patent portfolios; - In June 2014, we acquired Selene Communication Technologies, LLC, which holds multiple patents in the search and network intrusion field; - In August 2014, we acquired patents from Clouding IP LLC, with such patents related to network and data management technology; - In September 2014, we acquired TLI Communications, which owns a single patent in the telecommunication field; - In October 2014, we acquired three patent portfolios from MedTech Development, which owns medical technology patents; - In April 2015, we acquired forty-three international patents from Bridgestone Americas Tire Operation LLC, with such patents related to tire pressure monitoring sensors and systems. As of September 30, 2015, the Company’s patent portfolios consist of 369 U.S. and foreign patents and contract rights to ten patents. In the aggregate, the earliest date for expiration of a patent in the Company’s patent portfolio is past (the patent is expired, but patent rules allow for six year look-back for royalties), the median expiration date for patents in the Company’s portfolio is June 17, 2017, and the latest expiration date for a patent in any of the Company’s patent portfolios is July 29, 2029. A summary of the Company’s patent portfolios is as follows: Subsidiary Number of Patents Earliest Expiration Date Median Expiration Date Latest Expiration Date Subject Matter Bismarck IP Inc. 09/15/15 09/15/16 01/22/18 Communication and PBX equipment Clouding Corp. Expired 10/05/21 03/29/29 Network and data management CRFD Research, Inc. 09/17/21 08/11/22 08/19/23 Web page content translator and device-to-device transfer system Cyberfone Systems, LLC Expired 01/31/17 06/07/20 Telephony and data transactions Dynamic Advances, LLC Expired 10/02/17 03/06/23 Natural language interface E2E Processing, Inc. 04/27/20 11/17/23 07/18/24 Manufacturing schedules using adaptive learning Hybrid Sequence IP, Inc. 11/14/15 09/09/16 07/17/17 Asynchronous communications IP Liquidity Ventures, LLC Expired 04/09/17 07/26/20 Pharmaceuticals / tire pressure systems Loopback Technologies, Inc. Expired 09/25/17 08/27/22 Automotive Medtech Group Acquisition Corp. Expired 06/01/18 07/29/29 Medical technology Relay IP, Inc. Expired Expired Expired Multicasting Sampo IP, LLC 03/13/18 03/13/18 11/16/23 Centrifugal communications Sarif Biomedical LLC Expired Expired Expired Microsurgery equipment Selene Communication Technologies, LLC 05/05/18 11/23/20 11/28/21 Communications Signal IP, Inc. Expired 12/01/15 08/06/22 Automotive TLI Communications, LLC 06/17/17 06/17/17 06/17/17 Telecommunications Vantage Point Technology, Inc. Expired 12/21/16 03/09/18 Computer networking and operations

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
NOTE 5 - STOCKHOLDERS' EQUITY	NOTE 5 - STOCKHOLDERS’ EQUITY On December 7, 2011, the Company increased its authorized capital to 200,000,000 shares of Common Stock from 75,000,000 shares, changed the par value to $0.0001 per share from $.001 per share, and authorized 100,000,000 shares of preferred stock, par value $0.0001 per share. On June 24, 2013, the reverse stock split ratio of one (1) for thirteen (13) basis was approved by the Board of Directors. On July 18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock, par value $0.0001 per share on a one (1) for thirteen (13) basis. On November 19, 2014, the Board of Directors of the Company declared a stock dividend pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 shall receive one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders, which resulted in an increase in the number of outstanding shares of common stock by 6,895,730. All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split and stock dividend. Series B Convertible Preferred Stock On May 1, 2014, the Company filed with the Secretary of State of Nevada a Certificate of Designations of Series B Convertible Preferred Stock (the “Series B Certificate of Designations”) authorizing 500,000 shares of Series B Convertible Preferred Stock and establishing the designations, preferences, and other rights of the Series B Convertible Preferred Stock. The Series B Certificate of Designations became effective upon filing. On May 2, 2014, the Company issued an aggregate of 782,000 shares of Series B Convertible Preferred Stock valued at $2,807,380 to acquire IP Liquidity Ventures, LLC, Dynamic Advances, LLC and Sarif Biomedical, LLC. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act of 1933, as amended, by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering. On September 17, 2014, the Company entered into a consulting agreement (the “GRQ Consulting Agreement”) with GRQ Consultants, Inc. (“GRQ”), pursuant to which GRQ shall provide certain consulting services including, but not limited to, advertising, marketing, business development, strategic and business planning, channel partner development and other functions intended to advance the business of the Company. As consideration, GRQ shall be entitled to 200,000 shares of the Company’s Series B Convertible Preferred Stock, 50% of which vested upon execution of the GRQ Consulting Agreement, and 50% of which shall vest in six (6) equal monthly installments of commencing on October 17, 2014. The first tranche of 100,000 shares of Series B Convertible Preferred Stock was issued to GRQ on October 6, 2014. In addition, the GRQ Consulting Agreement allows for GRQ to receive additional shares of Series B Convertible Preferred Stock upon the achievement of certain performance benchmarks. All shares of Series B Convertible Preferred Stock issuable to GRQ shall be pursuant to the 2014 Plan (as defined below) and were subject to shareholder approval of the 2014 Plan on or prior to September 16, 2015, with such approval being received by the shareholders at the Company’s annual shareholder meeting held on July 31, 2015. The GRQ Consulting Agreement contains an acknowledgement that the conversion of the preferred stock into shares of the Company’s common stock is precluded by the equity blockers set forth in the certificate of designation and in Section 17 of the 2014 Plan to ensure compliance with NASDAQ Listing Rule 5635(d). In a series of transactions, the Series B Convertible Preferred Stock associated with the GRQ Consulting Agreement was converted into shares of the Company’s Common Stock, with 183,330 shares of Series B Convertible Preferred Stock converted into Common Stock prior to September 30, 2015. Common Stock On June 24, 2013, the reverse stock split ratio of one (1) for thirteen (13) basis was approved by the Board of Directors. On July 18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock , par value $0.0001 per share on a one (1) for thirteen (13) basis. All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split. On April 22, 2014, the Company issued 300,000 shares of Restricted Common Stock to TT IP LLC pursuant to the acquisition of patents on November 13, 2013. On June 2, 2014, the Company issued 48,078 shares of unrestricted Common Stock to an investor in the May 2013 PIPE, pursuant to the exercise of a warrant received in the May 2013 PIPE investment. On June 30, 2014, the Company issued 200,000 shares of Restricted Common Stock pursuant to the acquisition of Selene Communications Technologies, LLC (see Note 3). In connection with this transaction, the Company valued the shares at the fair market value on the date of grant at $4.90 per share or $980,000. On July 18, 2014, the Company issues a total of 26,722 shares of Common Stock pursuant to the exercise of stock options held by a former member of the Company’s Board of Directors and the Company’s former Chief Financial Officer. On September 16, 2014, the Company issued to two of its independent board members, in lieu of cash compensation, 6,178 shares of Restricted Common Stock . The shares shall vest quarterly over twelve (12) months commencing on the date of grant. On September 30, 2014, the Company issued 50,000 shares of Restricted Common Stock pursuant to the acquisition of the assets of Clouding IP, LLC (see Note 3). In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $5.62 per share or $281,000. For the three months ended September 30, 2014, certain holders of warrants exercised their warrants in a cashless, net exercise basis in exchange for 84,652 shares of the Company’s Common Stock. On November 19, 2014, the Board of Directors of the Company declared a stock dividend (“Dividend”) pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 shall receive one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders. Throughout this report, all share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the stock dividend. For the three months ended December 31, 2014, certain holders of warrants exercised their warrants in a cashless, net exercise basis in exchange for 29,230 shares of the Company’s Common Stock. On January 29, 2015, the Company issued 134,409 shares of the Company’s Common Stock to DBD Credit Funding, LLC (“DBD”), an affiliate of Fortress Credit Corp. (“Fortress”), pursuant to the Fortress transaction as set forth in Note 6. For the three months ended March 31, 2015, certain holders of warrants exercised their warrants to purchase, in cash, 5,000 shares of the Company’s Common Stock. For the three months ended June 30, 2015, certain holders of warrants exercised their warrants to purchase, on a net exercise basis, 33,968 (net) shares of the Company’s Common Stock. On July 24, 2015, the Company issued 200,000 shares of the Company’s Common Stock to MedTech Development pursuant to a forbearance agreement the Company entered into on July 16, 2015 with MedTech Development, the holder of a Promissory Note issued by the Company, dated October 10, 2014, as part of the consideration for the purchase price of the Medtech Entities. On September 21, 2015, the Company issued 150,000 shares of the Company’s Common Stock, in the amount of 90,000 and 60,000 shares with a stock price of $2.23 per share and a total value of $334,500, to two consultants pursuant to investor relations services the consultants are providing for the Company. In a series of transactions, the Series B Convertible Preferred Stock associated with the GRQ Consulting Agreement was converted into shares of the Company’s Common Stock, with 183,330 shares of Series B Convertible Preferred Stock converted into Common Stock prior to September 30, 2015. Common Stock Warrants On May 1, 2014, the Company issued warrants to purchase 511,790 shares of Common Stock, at a price of $3.75 per share of Common Stock, pursuant to the Private Placement described in detail below. The Company reviewed the issuance of warrants, done in conjunction with the financing closed on May 1, 2014, and determined that pursuant to ASC 480 and ASC 815, the warrants met the requirement to be classified as equity and were booked as Additional Paid-in Capital. In conjunction with the issuance of $5,550,000 in convertible debt on October 16, 2014, the Company issued two-year warrants to purchase 258,998 shares of the Company’s Common Stock, par value $0.0001 per share pursuant to a securities purchase agreement. The warrants were valued at $164,020 and were recorded as a discount to the fair value of the convertible notes. The warrants are initially convertible into shares of the Company’s Common Stock at an exercise price of $8.25 per share. The conversion and exercise prices are subject to adjustment in the event of certain events, including stock splits and dividends. The Company reviewed the instruments in the context of ASC 480 and determined that the convertible notes should be recorded as a liability and analyzed the conversion feature and bifurcation pursuant to ASC 815 and ASC 470, respectively, to determine that the was no beneficial conversion feature and that the convertible notes should not be bifurcated. On January 29, 2015, the Company and certain of its subsidiaries entered into a series of Agreements including a Securities Purchase Agreement (“Fortress Purchase Securities Agreement”) with DBD, an affiliate of Fortress, under which the Company issued a five-year warrant (“Fortress Warrant”) to purchase 100,000 shares of the Company’s Common Stock exercisable at $7.44 per share, subject to adjustment. The Company reviewed the instruments in the context of ASC 480 and determined that the convertible notes should be recorded as a liability and analyzed the conversion feature and bifurcation pursuant to ASC 815 and ASC 470, respectively, to determine that the was no bifurcation of the beneficial conversion feature and warrants were recorded as an equity. During the three and nine months ended September 30, 2015, the Company recorded compensation expense of $0 and $3,465, respectively, in connection with vested warrants. At September 30, 2015, there was a total of $0 of unrecognized compensation expense related to this non-vested warrant-based compensation arrangement. A summary of the status of the Company’s outstanding stock warrants at September 30, 2015 is as follows: Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Life Balance at December 31, 2014 $ Granted $ Cancelled - - - Forfeited - - - Exercised $ - Balance at September 30, 2015 Warrants exercisable at Septmeber 30, 2015 Weighted average fair value of warrants granted during the period $ Warrant Amendment Letter On April 20, 2014, the Company sent a letter (the “Warrant Amendment Letter”) to all the holders of the warrants which were granted in connection with the sale of units pursuant to a securities purchase agreements which occurred between May 2013 and August 2013. The Warrant Amendment Letter offered to reduce the exercise price of the warrants from $6.50 per share to $5.75 per share, if the holders of the warrants accepted the Company’s offer to exercise the warrants in full for cash by April 22, 2014 (the “Expiration Date”). The Company subsequently extended the Expiration Date to April 24, 2014. On April 24, 2014, one holder of warrants, who is an accredited investor, accepted the Company’s offer and thereby exercised his warrants, for gross proceeds to the Company of approximately $138,222. After analyzing the circumstances relative to the Warrant Amendment Letter – the extremely short period of time to exercise pursuant to the Amendment Letter, the relatively small change in the exercise price and the limited response to the Amendment Letter – the Company deemed that the change was not a significant modification of the terms of the warrant and did not assess a new fair value and consequently did not make an entry for any adjustment in the value. Common Stock Options On April 15, 2014, the Company issued a new board member a five (5) year option to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $3.295 per share, subject to adjustment, which shall vest in twelve (12) monthly installments commencing on the date of grant. The option was valued based on the Black-Scholes model, using the strike and market prices of $3.295 per share, life of three years, volatility of 51% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 0.84%. On May 14, 2014, the Company issued existing employees, ten (10) year options to purchase an aggregate of 80,000 shares of the Company’s Common Stock with an exercise price of $4.165 per share, subject to adjustment, which shall vest in three (3) annual installments, with 33% vesting on the first anniversary of the date of grant, 33% on the second anniversary of the date of grant and 34% on the third anniversary of the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 6.5 years, volatility of 63% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.97%. On May 14, 2014, the Company issued to consultants, five (5) year options to purchase an aggregate of 160,000 shares of the Company’s Common Stock with an exercise price of $4.165 per share, subject to adjustment, which shall vest in three (3) annual installments, with 33% vesting on the first anniversary of the date of grant, 33% on the second anniversary of the date of grant and 34% on the third anniversary of the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 3.5 years, volatility of 50% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.00%. On May 15, 2014, the Company entered into an executive employment agreement with Francis Knuettel II (“Knuettel Agreement”) pursuant to which Mr. Knuettel would serve as the Company’s Chief Financial Officer. As part of the consideration, the Company agreed to grant Mr. Knuettel a ten (10) year stock option to purchase an aggregate of 290,000 shares of Common Stock, with a strike price of $4.165 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Knuettel Agreement. The option was valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 6.5 years, volatility of 63% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.97%. On June 15, 2014, the Company issued to a consultant a five (5) year stock option to purchase an aggregate of 40,000 shares of the Company’s Common Stock with an exercise price of $5.05 per share, subject to adjustment, which shall vest in twenty-four (24) each monthly installments on each monthly anniversary date of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $5.05 per share, life of 3.25 years, volatility of 50% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.05%. On August 29, 2014, the Company entered into an executive employment agreement with Daniel Gelbtuch (“Gelbtuch Agreement”) pursuant to which Mr. Gelbtuch would serve as the Company’s Chief Marketing Officer. As part of the consideration, the Company agreed to grant Mr. Gelbtuch ten (10) year stock options to purchase an aggregate of 290,000 shares of Common Stock, with a strike price of $5.62 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Gelbtuch Agreement. Mr. Gelbtuch’s employment with the Company was terminated as of January 20, 2015 and the vested shares at that time remain available for Mr. Gelbtuch to exercise. The option was valued based on the Black-Scholes model, using the strike and market prices of $5.62 per share, life of 6.5 years, volatility of 62% based on the average volatility of comparable companies over the prior 10-year period and a discount rate as published by the Federal Reserve of 1.95%. On September 16, 2014, the Company issued its independent board members five (5) year options to purchase an aggregate of 60,000 shares of the Company’s Common Stock with an exercise price of $7.445 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.445 per share, life of three years, volatility of 49% based on the average volatility of comparable companies over the prior 5-year period and a discount rate as published by the Federal Reserve of 1.04%. On October 31, 2014, the Company entered into an executive employment agreement with Enrique Sanchez (“Sanchez Agreement”) pursuant to which Mr. Sanchez would serve as the Company’s Senior Vice President of Licensing. As part of the consideration, the Company agreed to grant Mr. Sanchez ten (10) year stock options to purchase an aggregate of 160,000 shares of Common Stock, with a strike price of $6.40 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Sanchez Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%. On October 31, 2014, the Company entered into an executive employment agreement with Umesh Jani (“Jani Agreement”) pursuant to which Mr. Jani would serve as the Company’s Chief Technology Officer and SVP of Licensing. As part of the consideration, the Company agreed to grant Mr. Jani ten (10) year stock options to purchase an aggregate of 100,000 shares of Common Stock, with a strike price of $6.40 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Jani Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%. On October 31, 2014, the Company issued existing employees, ten (10) year options to purchase an aggregate of 680,000 shares of the Company’s Common Stock with an exercise price of $6.40 per share, subject to adjustment, which shall vest in twenty-four (24) equal installments on each monthly anniversary . The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%. On October 31, 2014, the Company issued to a consultant, a five (5) year options to purchase an aggregate of 30,000 shares of the Company’s Common Stock with an exercise price of $6.40 per share, subject to adjustment, which shall vest in twenty-four (24) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 3.25 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.03%. On February 5, 2015 the Company issued to a consultant, a five (5) year options to purchase an aggregate of 25,000 shares of the Company’s Common Stock with an exercise price of $6.80 per share, subject to adjustment, which shall vest in twenty-four (24) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.80 per share, an expected term of 3.25 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 0.92%. On March 6, 2015 the Company issued a new board member a five (5) year options to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $7.37 per share, subject to adjustment, which shall vest in twelve (12) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.37 per share, an expected term of 3.0 years, volatility of 41% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.16%. On March 18, 2015 the Company issued a new board member a five (5) year options to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $6.61 per share, subject to adjustment, which shall vest in twelve (12) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.61 per share, an expected term of 3.0 years, volatility of 41% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 0.92%. On April 7, 2015 (the “Effective Date”), the Company entered into a consulting agreement (the “Consulting Agreement”) with Richard Chernicoff, a member of the Company’s Board of Directors, pursuant to which Mr. Chernicoff shall provide certain services to the Company, including serving as the interim General Counsel and interim General Manager of commercial product commercialization development. Pursuant to the terms of the Consulting Agreement, Mr. Chernicoff shall receive a monthly retainer of $27,000 and subject to shareholder approval and pursuant to the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), a ten (10) year stock option to purchase 280,000 shares of the Company’s common stock (the “Award”). The stock options shall have an exercise price of $6.76 per share, the closing price of the Company’s common stock on the date immediately prior to the Board of Directors approval of such stock options and the options shall vest as follows: 25% of the Award shall vest on the 12 month anniversary of the Effective Date and thereafter 2.083% on the 21st day of each succeeding calendar month for the following twelve months, provided Mr. Chernicoff continues to provide services (in addition to as a member of the Company’s Board of Directors) at the time of vesting. The Award shall be subject in all respects to the terms of the 2014 Plan. Notwithstanding anything herein to the contrary, the remainder of the Award shall be subject to the following as an additional condition of vesting: (A) options to purchase 70,000 shares of the Company’s common stock under the Award shall not vest at all unless the price of the Company’s common stock while Mr. Chernicoff continues as an officer and/or director reach $8.99 and (B) options to purchase 70,000 shares of the Company’s common stock under the Award shall not vest at all unless the price of the Company’s common stock while Mr. Chernicoff continues as an officer and/or director reach $10.14. For valuation purposes, the options were divided into two parts – the time-based vesting component and the performance-based vesting component. The time-based vesting component was valued based on the Black-Scholes model, using the strike and market prices of $6.76 per share, an expected term of 6.25 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.53%. The performace-based vesting component was valued based on the Monte Carlo Simulation model, using the strike and market prices of $6.76 per share, an expected term of 10.0 years, volatility of 61% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.89%. On September 16, 2015, the Company issued its independent board members ten (10) year options to purchase an aggregate of 80,000 shares of the Company’s Common Stock with an exercise price of $2.03 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $2.03 per share, an expected term of 5.5 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.72%. For the three and nine months ended September 30, 2015 the Company recorded option-based compensation expenses of $556,205 and $1,971,323, respectively and $ 450.004 and $1,364,243 for the three and nine months ended September 30, 2014, respectively. At September 30, 2015, there was a total of $2,975,214 of unrecognized compensation expense related to these non-vested option-based compensation arrangements discussed above. A summary of the stock options as of September 30, 2015 is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Life Balance at December 31, 2014 $ Granted $ Cancelled - $ - - Forfeited $ - Exercised $ - Balance at September 30, 2015 $ Options Exercisable at September 30, 2015 Options expected to vest Weighted average fair value of options granted during the period $ Stock options outstanding at September 30, 2015 as disclosed in the above table have no intrinsic value.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
NOTE 6 - COMMITMENTS AND CONTINGENCIES	NOTE 6 – COMMITMENTS AND CONTINGENCIES Fortress Transaction On January 29, 2015, the Company and certain of its subsidiaries (each a “Subsidiary”) entered into a series of Agreements including Fortress Securities Agreement and a Subscription Agreement with DBD, an affiliate of Fortress, under which the Company sold to the purchasers: (i) $15,000,000 original principal amount of Senior Secured Notes (“Fortress Notes”), (ii) a right to receive a portion of certain proceeds from monetization net revenues received by the Company (after receipt by the Company of $15,000,000 of monetization net revenues and repayment of the Fortress Notes), (the “Revenue Stream”), (iii) a five-year Fortress Warrant to purchase 100,000 shares of the Company’s Common Stock exercisable at $7.44 per share, subject to adjustment; and (iv) 134,409 shares of the Company’s Common Stock. Under the Fortress Purchase Agreement, the Company has the right to require the purchasers to purchase an additional $5,000,000 of Notes (which will increase proportionately the Revenue Stream), subject to the achievement of certain milestones, and further contemplates that Fortress may, but is not obligated to, fund up to an additional $30,000,000, on equivalent economic terms. The Company may use the proceeds to finance the monetization of its existing assets, provide further expansion capital for new acquisitions, to repay existing debt (including without limitation, the Company’s 11% convertible notes issued October 9, 2013 and for general working capital and corporate purposes. Pursuant to the Purchase Agreement entered into on January 29, 2015, the Company issued to Fortress a Note in the original principal amount of $15,000,000 (the “Initial Note”). The Initial Note matures on July 29, 2018. If any additional Notes are issued pursuant to the Fortress Securities Purchase Agreement, the maturity date of such additional Fortress Notes shall be 42 months after issuance. The unpaid principal amount of the Initial Note (including any PIK Interest, as defined below) shall bear cash interest at a rate equal to LIBOR plus 9.75% per annum; provided that upon and during the continuance of an Event of Default (as defined in the Fortress Securities Purchase Agreement), the interest rate shall increase by an additional 2% per annum. As of Septemner 30, 2015, the twelve-month LIBOR USD rate was 0.84735%. Interest on the Initial Note shall be paid on the last business day of each calendar month (the “Interest Payment Date”), commencing January 31, 2015. Interest shall be paid in cash except that 2.75% per annum of the interest due on each Interest Payment Date shall be paid-in-kind, by increasing the principal amount of the Notes by the amount of such interest, effective as of the applicable Interest Payment Date (“PIK Interest”). PIK Interest shall be treated as added principal of the Initial Note for all purposes, including interest accrual and the calculation of any prepayment premium. The Fortress Securities Purchase Agreement contains certain customary events of default, and also contains certain covenants including a requirement that the Company maintain minimum liquidity of $1,000,000 in unrestricted cash and cash equivalents and that the Company shall have Monetization Revenues (as defined in the Fortress Purchase Agreement) for the four fiscal quarters commencing December 31, 2014 of at least $15,000,000. For the two quarters since the inception of this covenant, the Company has booked $5,462,855 in revenue, less than half of the amount necessary to fulfill this covenant. The terms of the Fortress Warrant provide that until January 29, 2020, the Fortress Warrant may be exercised for cash or on a cashless basis. Exercisability of the Fortress Warrant is limited if, upon exercise, the holder would beneficially own more than 4.99% of the Company’s Common Stock. As part of the transaction, DBD entered into a lock-up agreement (the “Lock-Up Agreement”) pursuant to which the parties and certain related holders agreed until the earlier of 12 months or acceleration of an Event of Default (as defined in the Fortress Securities Purchase Agreement), that they will not, directly or indirectly, (i) offer, sell, offer to sell, contract to sell, hedge, hypothecate, pledge, sell any option or contract to purchase any option or contract to sell, grant any option, right or warrant to purchase or sell (or announce any offer, sale, offer of sale, contract of sale, hedge, hypothecation, pledge, sale of any option or contract to purchase, purchase of any option or contract of sale, grant of any option, right or warrant to purchase or other sale or disposition), or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future), the Lock-Up Shares (as defined in the Lock-Up Agreement), beneficially owned, within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), by such Holder and his/her Related Group (as such terms are defined in the Lock-Up Agreement) on the date of the Lock-Up Agreement or thereafter acquired or (ii) enter into any swap or other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Shares, whether or not any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of any Lock-Up Shares. The Holders may purchase additional shares of the Company’s Common Stock during the Lock-Up Period (as defined in the Lock-Up Agreement) to the extent that such purchase only increases the net holding of the Holders in the Company. In connection with the transactions described above, TechDev, Audrey Spangenberg, Erich Spangenberg, and Granicus (the “Spangenberg Holders”) entered into a lock-up agreement (the “Spangenberg Lockup”) with respect to 1,626,924 shares of Common Stock, 48,078 shares of Common Stock underlying warrants, and 782,000 shares of Common Stock underlying preferred stock, pursuant to which the Spangenberg Holders agreed that until payment in full of the Note Obligations (as defined in the Fortress Notes), which shall include but not be limited to all principal and interest on outstanding Notes pursuant to the Purchase Agreement, the Spangenberg Holders and certain related parties agreed that they will not, directly or indirectly, (i) offer, sell, offer to sell, contract to sell, hedge, hypothecate, pledge, sell any option or contract to purchase any option or contract to sell, grant any option, right or warrant to purchase or sell (or announce any offer, sale, offer of sale, contract of sale, hedge, hypothecation, pledge, sale of any option or contract to purchase, purchase of any option or contract of sale, grant of any option, right or warrant to purchase or other sale or disposition), or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future), more than 5% of the Spangenberg Lockup shares (as defined in the Spangenberg Lock-Up Agreement), beneficially owned, within the meaning of Rule 13d-3 under the Exchange Act, by such Holder and his/her Related Group (as such terms are defined in the Spangenberg Lock-Up Agreement) on the date of the Spangenberg Lock-Up Agreement or thereafter acquired or (ii) enter into any swap or other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of more than 5% of the Spangenberg Lock-Up Shares, whether or not any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of any Lock-Up Shares. The Spangenberg Holders may purchase additional shares of the Company’s Common Stock during the Lock-Up Period (as defined in the Spangenberg Lock-Up Agreement) to the extent that such purchase only increases the net holding of the Holders in the Company. Pursuant to the Fortress Securities Purchase Agreement, as security for the payment and performance in full of the Secured Obligations (as defined in the Fortress Securities Purchase Agreement) in favor of DBD, the Company and certain subsidiaries executed and delivered in favor of DBD a Security Agreement (“Security Agreement”) and a Patent Security Agreement (“Patent Security Agreement”), including a pledge of the Company’s interests in certain of its subsidiaries. As further set forth in the Security Agreement, repayment of the Note Obligations is secured by a first priority lien and security interest in all of the assets of the Company, subject to permitted liens on permitted indebtedness that existed as of January 29, 2015. The security interest does not include a lien on the assets held by Orthophoenix, LLC. Certain subsidiaries of the Company (excluding Orthophoenix) also executed guarantees in favor of the purchasers (each, a “Guaranty”), guaranteeing the Note Obligations. As required by the terms of certain notes issued by the Company in October 2014 (“October Notes”), the October Note holders consented to the transactions described herein. Within thirty days, the Company was required to open a cash collateral account into which all Company revenue shall be deposited and which shall be subject to a control agreement outlining the disbursement in accordance with the terms of the Fortress Securities Purchase Agreement of all proceeds. Pursuant to the Fortress Securities Purchase Agreement, the Company entered into the Fortress Patent License Agreement with DBD pursuant to which the Company agreed to grant to the Licensee certain rights, including right to license certain patents and patent applications, which licensing rights to be available solely upon an acceleration of the Note Obligations, as provided in the Fortress Securities Purchase Agreement. Office Lease In October 2013, the Company entered into a net-lease for its current office space in Los Angeles, California. The lease will commence on May 1, 2014 and runs for seven years through April 30, 2021, with monthly lease payment escalating each year of the lease. In addition, to paying a deposit of $7,564 and the monthly base lease cost, the Company is required to pay pro rata share of operating expenses and real estate taxes. Under the terms of the lease, the Company will not be required to pay rent for the first five months but must remain in compliance with the terms of the lease to continue to maintain that benefit. In addition, the Company has a one-time option to terminate the lease in the 42th month of the lease. Minimum future lease payments under this lease at September 30, 2015, for the next five years and thereafter are as follows: 2015 (Nine Months) $ 2016 2017 2018 2019 Thereafter Total $ Legal Proceedings In the ordinary course of business, we actively pursue legal remedies to enforce our intellectual property rights and to stop unauthorized use of our technology. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder are adverse to the Company or who has a material interest adverse to us. On August 14, 2014, Dominion Harbor Group, LLC (“Dominion”), a former vendor to the Company, filed a complaint against the Company in the Northern District of Texas for breach of contract, unjust enrichment and fraudulent inducement. On October 30, 2015, the Company and Dominion entered into a settlement agreement whereby the Company agreed to 1) pay Dominion $250,000, with $50,000 payable immediately and the remainder payable in eight equal payments over the next eight quarter starting on January 15, 2016 and 2) issue Dominion 300,000 restricted shares of the Company’s Common Stock, with 200,000 of these shares locked up until May 4, 2016 and the remaining 100,000 shares locked up until November 3, 12016. Other than as disclosed herein, we know of no other material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation other than in the normal course of business.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
NOTE 7 - SUBSEQUENT EVENTS	NOTE 7 – SUBSEQUENT EVENTS On October 16, 2015, the Company entered into a Patent Purchase Agreement whereby the Company acquired 31 United States and foreign patents in return for an interest in the net recoveries. On October 23, 2015, the Company entered into Amendment No. 1 to Forbearance Agreement (the “Amendment”) to the Forbearance Agreement entered into with MedTech Development on July 13, 2015. MedTech Development is the holder of a Promissory Note issued by the Company, dated October 10, 2014, which was issued by the Company as part of the consideration for the purchase price of the Medtech Entities. Pursuant to the Amendment, the due date of the Promissory Note was extended to October 23, 2016 in return for which the Company made a payment of $100,000 on October 23, 2015 and modified the terms under which the Company agreed to make mandatory prepayments under certain circumstances. On October 30, 2015, the Company and Dominion Harbor Group, LLC (“Dominion”) entered into a settlement agreement whereby the Company agreed to 1) pay Dominion $250,000 in cash, with $50,000 payable immediately and the remainder payable in eight equal payments over the next eight quarter starting on January 15, 2016 and 2) issue Dominion 300,000 restricted shares of the Company’s Common Stock, with 200,000 of these shares locked up until May 4, 2016 and the remaining 100,000 shares locked up until November 3, 2016. On November 16, 2015, the Company made a payment in the amount of $100,000 towards the remaining balance of the note to Medtronic pursuant to the purchase of the Medtech Entities and is negotiating with Medtronic to pay the remaining amount. On November 15, 2015, the Company entered into an agreement with Bridgestone Americas, Inc. (“Bridgestone”) whereby Bridgestone and the Company terminated the German Patent Purchase Agreement entered into on April 23, 2015. The effect of this is that effective November 15, 2015, the current book value of the patents will be removed from the Company's balance sheet as will the entirety of the debt associated with the purchase agreement in the amount of $10 million. The Company made no payments to Bridgestone pursuant to the German Patent Purchase Agreement.

SUMMARY OF SIGNIFICANT ACCOUN13

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2015
Summary Of Significant Accounting Policies Policies
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The unaudited consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and present the consolidated financial statements of the Company and its wholly-owned subsidiaries. In the preparation of consolidated financial statements of the Company, all intercompany transactions and balances were eliminated. All adjustments (consisting of normal recurring items) necessary to present fairly the Company’s consolidated financial position as of September 30, 2015, and the results of operations and cash flows for the three and nine months ended September 30, 2015 have been included. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the full year. Other than where noted, the accounting policies and procedures employed in the preparation of these consolidated financial statements have been derived from the audited financial statements of the Company for the year ended December 31, 2014, which are contained in Form 10-K as filed with the Securities and Exchange Commission (“SEC”) on March 26, 2015. The consolidated balance sheet as of December 31, 2014 was derived from those financial statements.
Cash	Cash The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. The Company’s accounts at this institution are insured up to $250,000 by the Federal Deposit Insurance Corporation (“FDIC”). As of September 30, 2015, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits. Pursuant to the agreement with Fortress, the Company has agreed to a minimum cash covenant in the amount of $1,000,000.
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.
Accounts Receivable	Accounts Receivable The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote. At September 30, 2015 and December 31, 2014, the allowance for bad debt was $0 and $0, respectively. Accounts receivable-net at September 30, 2015 and December 31, 2014, amounted to $2,326,717 and $216,997, respectively. As of September 30, 2015, accounts receivable related to two licenses accounted for approximately 81% of the Company’s total accounts receivable, accounts receivable related to recurring royalties represented approximately 3% of total accounts receivable and the Company had a receivable from an indemnification claim to be paid by the seller of a portfolio purchased by the Company in the amount of $375,750 or 16% of total accounts receivable. As of December 31, 2014, 86% of total accounts receivable were associated with outstanding recurring royalties and 14% were associated with one outstanding license payment.
Concentration of Revenue and Geographic Area	Concentration of Revenue and Geographic Area Patent license revenue from enforcement activities is from either the United States or Germany. Revenue attributable to the United States involves US patents; revenue attributable to Germany is based on the enforcement of German patents and in the event that the Company enters into a worldwide license, the revenue is allocated between the two. The Company does not currently have enforcement actions in any other countries. Revenues from five licenses accounted for approximately 87% of the Company’s operating revenues for the three months ended September 30, 2015 and revenue from five licenses accounting for 100% of the revenue for the three months ended September 30, 2014. For the Three Months Ended September 30, 2015 For the Three Months Ended September 30, 2014 Licensor License Amount % of Revenue Licensor License Amount % of Revenue Orthophoenix, LLC $ Clouding Corp. $ IP Liquidity Ventures, LLC Selene Communications Technologies, LLC $ TLI Communications LLc / TLI Communications GmbH $ Selene Communications Technologies, LLC $ Clouding Corp. $ Cyberfone Systems LLC $ Signal IP, Inc. $ Cyberfone Systems LLC $ Total Total While the Company has a growing portfolio of patents, the Company has historically received a significant portion of its revenue and expects that a significant portion of its future revenues will be based on one-time grants of similar non-recurring, non-exclusive, non-assignable licenses to a relatively small number of entities and their affiliates. Further, with the expected small number of firms with which the Company enters into license agreements, and the amount and timing of such license agreements, the Company also expects that its revenues may be highly variable from one period to the next.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 605, “Revenue Recognition”. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. The Company considers its licensing and enforcement activities as one unit of accounting under ASC 605-25, “Multiple-Element Arrangements” as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use, and the release. Also, due to the fact that the settlement element and license element for past and future use are the major central business, the Company does not present these two elements as different revenue streams in its statements of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. The Company derived approximately 97% and 100% of its revenues for the three months ended September 30, 2015 and September 30, 2014, respectively, and 94% and 100% of its revenues for the nine months ended September 30, 2015 and September 30, 2014, respectively, from the one-time issuance of non-recurring, non-exclusive, non-assignable licenses for certain of the Company’s patents, with the balance comprised of recurring royalties and Opus subscription fees. The Company’s subsidiaries entered into eleven license agreements during the three months ended September 30, 2015.
Cost of Revenue	Cost of Revenue Cost of revenue mainly includes expenses incurred in connection with the Company’s patent enforcement activities, such as legal fees, consulting costs, patent maintenance, royalty fees for acquired patents and other related expenses. Cost of revenue does not include patent amortization expenses, which are included as a separate line item in operating expenses and cost of revenue also does not include expenses related to product development, integration or support, as these are included in general and administrative expenses.
Prepaid Expenses, Bonds Posted and Other Current Assets	Prepaid Expenses, Bonds Posted and Other Current Assets Prepaid expenses and other current assets of $114,953 and $438,391 at September 30, 2015 and December 31, 2014, respectively, consist primarily of costs paid for future services and the unamortized portion of a convertible loan fee, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements. In addition, the Company had outstanding litigation bonds in the amount of $1,794,226 and $1,946,196 at September 30, 2015 and December 31, 2014, respectively. These bonds were entered into in Germany after the first instance of litigation of some of the Company’s patents in German courts and the difference in the balance of the litigation bonds at December 31, 2014 versus September 30, 2015 is attributable solely to currency translation.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company adopted FASB ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing US GAAP that require the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The carrying amounts reported in the consolidated balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company. Clouding IP earn out liability was determined as a Level 3 liability, which requires fair assessment of fair value at each period end by using discounted cash flow as valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of September 30, 2015, the Company determined Clouding IP earnout liability as $327,757 for current portion and $6,222,895 as long-term portion, which resulted in gain from exchange in fair value adjustment of $597,047 and $2,901,348 for three and nine months ended September 30, 2015, respectively. Further, the periodic reassessment resulted in non-routine impairment of Clouding patent intangible assets of $0 and $766,498 for the three and nine months ended September 30, 2015.
Accounting for Acquisitions	Accounting for Acquisitions In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses. With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 – Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis. The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.
Income Taxes	Income Taxes The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized. The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is highly certain that some positions taken would be situated upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits. The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For a tax position considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the previous year’s tax returns. After review of the prior year financial statements and the results of operations through September 30, 2015, the Company has recorded a deferred tax asset in the amount of $10,529,693, from which the Company expects to realize benefits in the future, and a deferred tax liability of $1,056,406. The Company files U.S. and state income tax returns with varying statutes of limitations. The 2011 through 2014 tax years generally remain subject to examination by federal and state tax authorities.
Basic and Diluted Net Earnings (Loss) per Share	Basic and Diluted Net Earnings (Loss) per Share Net earnings (loss) per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (“ASC 260”). Basic earnings (loss) per share is computed by dividing net earnings (loss) by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net earnings (loss) per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 2,886,392 shares of common stock and warrants to purchase 2,021,308 shares of common stock outstanding at September 30, 2015, which were excluded from the computation of diluted shares outstanding, as they would have had an anti-dilutive impact on the Company’s net loss. The following table sets forth the computation of basic and diluted loss per share: For the Three Months Ended September 30, 2015 For the Three Months Ended September 30, 2014 For the Nine Months Ended September 30, 2015 For the Nine Months Ended Septemer 30, 2014 Net income (loss) $ $ Denominator Weighted Average Common Shares - Basic Weighted Average Common Shares - Diluted Earnings (Loss) per common share: Income (Loss) - Basic $ $ $ $ Income (Loss) - Diluted $ $ $ $
Intangible Assets	Intangible Assets Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company performs the annual testing for impairment of intangible assets at the reporting unit level during the quarter ended September 30. The Company did not record any impairment charges to its intangible assets during the three months ended September 30, 2015 and 2014 and recorded impairment charges of $766,498 and $0 for the nine months ended September 30, 2015 and 2014, respectively.
Goodwill	Goodwill Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: 1. Significant underperformance relative to expected historical or projected future operating results; 2. Significant changes in the manner of use of the acquired assets or the strategy for the overall business; 3. Significant negative industry or economic trends; and 4. Significant reduction or exhaustion of the potential licenses of the patents which gave rise to the goodwill. When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired and the Company is not required to perform further testing. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30. The Company did not record any impairment charges to its goodwill during the three months ended September 30, 2015, whereas the Company recorded an impairment charge in the amount of $2,144,488 to the goodwill associated with CyberFone for the three months ended September 30, 2014 and recorded impairment charges to goodwill in the amount of $0 and $2,144,488 for the nine months ended September 30, 2015 and 2014, respectively.
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 “Property, Plant and Equipment”. The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The Company did not record any impairment charges on its long-lived assets during the three and nine months ended September 30, 2015 and 2014.
Stock-based Compensation	Stock-based Compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. As stock-based compensation expense is recognized based on awards expected to vest , forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the three and nine months ended September 30, 2015, the expected forfeiture rate was 11.66% and 11.66%, respectively, which resulted in an expense of $8,423 and $16,004, respectively, recognized in the Company’s compensation expenses. There were no forfeitures for the three and nine months ended September 30, 2014. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.
Reclassification	Reclassification Certain prior year reported amounts have been reclassified to conform to the current year presentation. The reclassification did not have an impact on previously issued net income (loss) or Total Shareholders’ Equity.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In September 2015, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, or ASU 2015-16. This amendment requires the acquirer in a business combination to recognize in the reporting period in which adjustment amounts are determined, any adjustments to provisional amounts that are identified during the measurement period, calculated as if the accounting had been completed at the acquisition date. Prior to the issuance of ASU 2015-16, an acquirer was required to restate prior period financial statements as of the acquisition date for adjustments to provisional amounts. The new standard for an annual reporting period beginning after December 15, 2017 with an earlier effective application is permitted only as of annual reporting periods beginning after December 15, 2016. The new guidance is not expected to have significant impact on the Company’s consolidated financial statements, In April 2015, the FASB issued ASU 2015-05, Intangibles-Goodwill and Other – Internal-Use Software; Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement . Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer’s accounting for fees paid in a cloud computing arrangement. Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The ASU does not change the accounting for service contracts. The new standard is effective for us on January 1, 2016 with early adoption permitted. We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements. In April 2015, the FASB issued new guidance on the presentation of debt issuance costs (ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs) , effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years and should be applied retrospectively to all periods presented. Early adoption of the new guidance is permitted for financial statements that have not been previously issued. The new guidance will require that debt issuance costs be presented in the balance sheet as a direct deduction from the related debt liability rather than as an asset, consistent with debt discounts. The Company adopted ASU 2015-03 and as such, the debt issuance costs for Fortress note was presented in the balance sheet as direct deduction from the related debt liability. In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. This standard update provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016. The new guidance is not expected to have significant impact on the Company’s consolidated financial statements. In May 2014, the Financial Accountings Standards Board ( “FASB” ) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers , or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and shall take effective on January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method and the early application of the standard is not permitted. The Company is presently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.

SUMMARY OF SIGNIFICANT ACCOUN14

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2015
Summary Of Significant Accounting Policies Tables
Schedule of Concentration of Revenue and Geographic Area	For the Three Months Ended September 30, 2015 For the Three Months Ended September 30, 2014 Licensor License Amount % of Revenue Licensor License Amount % of Revenue Orthophoenix, LLC $ Clouding Corp. $ IP Liquidity Ventures, LLC Selene Communications Technologies, LLC $ TLI Communications LLc / TLI Communications GmbH $ Selene Communications Technologies, LLC $ Clouding Corp. $ Cyberfone Systems LLC $ Signal IP, Inc. $ Cyberfone Systems LLC $ Total Total
Schedule of Basic and Diluted Loss Per Share	For the Three Months Ended September 30, 2015 For the Three Months Ended September 30, 2014 For the Nine Months Ended September 30, 2015 For the Nine Months Ended Septemer 30, 2014 Net income (loss) $ $ Denominator Weighted Average Common Shares - Basic Weighted Average Common Shares - Diluted Earnings (Loss) per common share: Income (Loss) - Basic $ $ $ $ Income (Loss) - Diluted $ $ $ $

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	9 Months Ended
	Sep. 30, 2015
CyberFone [Member]
Net purchase price paid, assets and liabilities	Intangible assets $ Goodwill Net purchase price $
Selene Communication Technologies [Member]
Net purchase price paid, assets and liabilities	Intangible assets $ Net working capital Goodwill Net purchase price $
Clouding Corp [Member]
Net purchase price paid, assets and liabilities	Intangible assets $ Goodwill Net purchase price $ Total consideration paid of the following: Cash $ Promissory Note Common Stock Earn Out Liability Net purchase price $
TLI Communications LLC [Member]
Net purchase price paid, assets and liabilities	Intangible assets $ Goodwill Net purchase price $
Medtech Entities
Net purchase price paid, assets and liabilities	Intangible assets $ Goodwill Net purchase price $

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2015
Intangible Assets Tables
Schedule of Intangible Assets	September 30, 2015 December 31, 2014 Intangible Assets $ $ Accumulated Amortization & Impairment Intangible assets, net $ $
Schedule of Amortization Expense	2015 $ 2016 2017 2018 2019 2020 and thereafter Total $
Summary of the Company's patent portfolios	Subsidiary Number of Patents Earliest Expiration Date Median Expiration Date Latest Expiration Date Subject Matter Bismarck IP Inc. 09/15/15 09/15/16 01/22/18 Communication and PBX equipment Clouding Corp. Expired 10/05/21 03/29/29 Network and data management CRFD Research, Inc. 09/17/21 08/11/22 08/19/23 Web page content translator and device-to-device transfer system Cyberfone Systems, LLC Expired 01/31/17 06/07/20 Telephony and data transactions Dynamic Advances, LLC Expired 10/02/17 03/06/23 Natural language interface E2E Processing, Inc. 04/27/20 11/17/23 07/18/24 Manufacturing schedules using adaptive learning Hybrid Sequence IP, Inc. 11/14/15 09/09/16 07/17/17 Asynchronous communications IP Liquidity Ventures, LLC Expired 04/09/17 07/26/20 Pharmaceuticals / tire pressure systems Loopback Technologies, Inc. Expired 09/25/17 08/27/22 Automotive Medtech Group Acquisition Corp. Expired 06/01/18 07/29/29 Medical technology Relay IP, Inc. Expired Expired Expired Multicasting Sampo IP, LLC 03/13/18 03/13/18 11/16/23 Centrifugal communications Sarif Biomedical LLC Expired Expired Expired Microsurgery equipment Selene Communication Technologies, LLC 05/05/18 11/23/20 11/28/21 Communications Signal IP, Inc. Expired 12/01/15 08/06/22 Automotive TLI Communications, LLC 06/17/17 06/17/17 06/17/17 Telecommunications Vantage Point Technology, Inc. Expired 12/21/16 03/09/18 Computer networking and operations

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2015
Stockholders Equity Tables
Status of outstanding stock warrants	Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Life Balance at December 31, 2014 $ Granted $ Cancelled - - - Forfeited - - - Exercised $ - Balance at September 30, 2015 Warrants exercisable at Septmeber 30, 2015 Weighted average fair value of warrants granted during the period $
Summary of stock options	Number of Options Weighted Average Exercise Price Weighted Average Remaining Life Balance at December 31, 2014 $ Granted $ Cancelled - $ - - Forfeited $ - Exercised $ - Balance at September 30, 2015 $ Options Exercisable at September 30, 2015 Options expected to vest Weighted average fair value of options granted during the period $

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Schedule of leases	2015 (Nine Months) $ 2016 2017 2018 2019 Thereafter Total $

ORGANIZATION AND DESCRIPTION 19

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative)	Jun. 24, 2013	May. 31, 2013	Oct. 01, 2012	Sep. 30, 2015patent$ / sharesshares	Dec. 31, 2014$ / sharesshares	Nov. 19, 2014shares	Jul. 18, 2013$ / shares	Aug. 01, 2012shares	Dec. 07, 2011$ / sharesshares	Dec. 06, 2011$ / sharesshares
Patents Owned | patent				369
Patent Applications | patent				10
Authorized shares of common stock				200,000,000	200,000,000				200,000,000	75,000,000
Common stock par value | $ / shares				$ 0.0001	$ 0.0001		$ 0.0001		$ 0.0001	$ 0.001
Authorized shares of preferred stock				50,000,000	50,000,000				50,000,000
Preferred stock par value | $ / shares				$ 0.0001	$ 0.0001				$ 0.0001
Shares reserved for issuance under plan								10,000,000
Reverse split	one (1) for thirteen (13)		3-for-2
Reverse stock split time to effectuate			1 year
Stock dividend (in shares)						1
Minimum
Reverse split		one-for-five
Maximum
Reverse split		one-for-fifteen

SUMMARY OF SIGNIFICANT ACCOUN20

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Orthophoenix LLC Member
License Amount	$ 2,050,000	$ 10,500,000
Percent of revenue	32.00%	78.00%
IP Liquidity Ventures, LLC [Member]
License Amount	$ 1,800,000
Percent of revenue	28.00%
TLI Communications LLC Member
License Amount	$ 800,000	$ 2,900,000
Percent of revenue	13.00%	22.00%
Clouding Corp [Member]
License Amount	$ 500,000	$ 35,472
Percent of revenue	8.00%
Signal IP Inc Member
License Amount	$ 400,000	$ 10,000
Percent of revenue	6.00%

SUMMARY OF SIGNIFICANT ACCOUN21

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Summary Of Significant Accounting Policies Details 1
Net loss	$ (3,750,468)	$ 3,522,604	$ (13,034,736)	$ 1,652,250
Weighted-Average Number of Shares Outstanding - Basic	14,376,118	11,500,500	14,094,891	11,197,374
Weighted-Average Common Shares - Diluted	14,376,118	15,966,454	14,094,891	14,926,504
Income (loss) - Basic	$ (0.26)	$ 0.31	$ (0.92)	$ 0.15
Income (loss) - Diluted	$ (0.26)	$ 0.22	$ (0.92)	$ 0.11
Impairment charges			$ 766,498	$ 0
Goodwill Impairment Loss		$ 2,144,488	$ 0	$ 2,144,488

SUMMARY OF SIGNIFICANT ACCOUN22

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)agreementshares	Sep. 30, 2014USD ($)agreement	Sep. 30, 2015USD ($)agreementshares	Sep. 30, 2014USD ($)agreement	Dec. 31, 2014USD ($)
Cash, FDIC Insured Amount	$ 250,000		$ 250,000
Allowance for bad debt	0		0		$ 0
Accounts receivable-net	$ 2,326,717		$ 2,326,717		$ 216,997
Collection of revenue as Accounts receivable related to two licenses	81.00%		81.00%
Collection of accounts receivable related to recurring royalties	3.00%		3.00%
Received idemnifiication claim	$ 375,750		$ 375,750
Indemnification claim as related to accounts receivable	16.00%		16.00%
Percent of total A/R associated with outstanding recurring royalties					86.00%
Percent of A/R associated with outstanding outstanding license payment					14.00%
Revenues from five licenses	87.00%	100.00%
Percent of revenue from one-time issuance of non-recurring, non-exclusive, non-assignable licenses for certain patents	97.00%	100.00%	94.00%	100.00%
Number of new license agreements | agreement	11
Prepaid expenses and other current assets	$ 114,953		$ 114,953		$ 438,391
Outstanding litigation bonds	1,794,226		1,794,226		1,946,196
Clouding IP earn out - current portion	327,757		327,757		2,092,000
Clouding IP earn out	6,222,895		6,222,895		7,360,000
Deferred tax asset	10,529,693		10,529,693		4,789,293
Deferred tax liability	$ 1,056,406		$ 1,056,406		$ 1,823,884
Option to purchase common stock | shares	2,886,392		2,886,392
Warrants to purchase shares of common stock | shares	2,021,308		2,021,308
Expected forfeiture rate	11.66%		11.66%
Compensation expenses	$ 8,423	$ 0	$ 16,004	$ 0
Decrease in earnout payment	$ 597,047		$ 2,901,348
Cash covenant			minimum cash covenant in the amount of $1,000,000.
Customer Concentration Risk [Member]
Number of licenses | agreement	5	5	5	5
Credit Concentration Risk [Member]
Number of licenses | agreement	2		2

ACQUISITIONS (Details)

ACQUISITIONS (Details)	Jun. 21, 2013USD ($)	Apr. 22, 2013USD ($)patent$ / sharesshares	Sep. 30, 2014USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)patent	Sep. 30, 2015USD ($)item	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)
Number of Patents (in patents)					369	7
Fair value of common stock issued								$ 281,000
Promissory note payment							$ 1,109,375	937,500
Impairment of goodwill				$ 2,144,488			0	$ 2,144,488
Goodwill					$ 4,573,450	$ 4,573,450	$ 4,573,450		$ 4,894,208
CyberFone [Member]
Ownership interest held (as a percent)		100.00%
Number of pending patents (in patents)		1
Consideration paid		$ 500,000
Promissory note issued		$ 500,000
Promissory note payment	$ 500,000
Recovery percentage payout period		30 days
Recovery of licensing or enforcement activities on patents		$ 4,000,000
Impairment of goodwill			$ 2,144,488
Intangible assets		1,135,512
Goodwill		2,144,488
Net purchase price		$ 3,280,000
CyberFone [Member] | Foreign
Number of Patents (in patents) | patent		27
CyberFone [Member] | United States
Number of Patents (in patents) | patent		10
CyberFone [Member] | Pre-Split
Common stock issued (in shares) | shares		6,000,000
Fair value on grant date (in dollars per share) | $ / shares		$ 0.38
CyberFone [Member] | Post-Split
Common stock issued (in shares) | shares		461,538
Fair value on grant date (in dollars per share) | $ / shares		$ 4.94
Fair value of common stock issued		$ 2,280,000

ACQUISITIONS (Details 2)

ACQUISITIONS (Details 2)	Apr. 01, 2015USD ($)	May. 02, 2014USD ($)paymentshares	May. 02, 2013USD ($)payment	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)shares	Dec. 31, 2014shares
Shares issued (in shares) | shares					798,670	932,000
Dynamic Advances [Member]
Ownership interest held (as a percent)			100.00%
Cash payments made (in payments) | payment			2
Consideration paid			$ 2,375,000		$ 6,653,078
Second payment amount after June 30, 2014			$ 2,850,000
Maximum possible amount of future payments		$ 250,000,000
Promissory note issued		2,375,000
Promissory note amount upon late payment		$ 2,850,000
Payment agreement to extend maturity date				$ 249,375
Note term				30 days
Dynamic Advances [Member] | Series B Convertible Preferred Stock
Shares issued (in shares) | shares		195,500
IP Liquidity [Member]
Ownership interest held (as a percent)		100.00%
Cash payments made (in payments) | payment		2
Consideration paid	$ 2,850,000	$ 2,375,000
Second payment amount after June 30, 2014					2,850,000
Maximum possible amount of future payments		250,000,000
Promissory note issued		2,375,000
Promissory note amount upon late payment		$ 2,850,000
Payment agreement to extend maturity date				$ 249,375
Note term				30 days
Consideration paid, including capitalized costs					6,653,078
IP Liquidity [Member] | Series B Convertible Preferred Stock
Shares issued (in shares) | shares		195,500
Sarif Biomedical [Member]
Ownership interest held (as a percent)		100.00%
Cash payments made (in payments) | payment		2
Consideration paid		$ 250,000			$ 552,024
Second payment amount after June 30, 2014		300,000
Maximum possible amount of future payments		250,000,000
Promissory note issued		250,000
Promissory note amount upon late payment		$ 300,000
Payment agreement to extend maturity date				$ 26,250
Note term				30 days

ACQUISITIONS (Details 3)

ACQUISITIONS (Details 3) - Acquisitions Member	Nov. 02, 2014	May. 02, 2014USD ($)
Purchase agreements (in agreements)		3
Pay Proceeds Agreement Member | Maximum
Recovery amount		$ 250,000,000
Registration Rights Agreement Member | Maximum
Registration statements required to be filed (in statements)	3
Filing period	60 days
$10,000,000 or less | Pay Proceeds Agreement Member | Maximum
Recovery amount		$ 10,000,000
$10,000,000 to $40,000,000 | Pay Proceeds Agreement Member
Net recovery proceeds due to sellers (as a percent)		40.00%
$10,000,000 to $40,000,000 | Pay Proceeds Agreement Member | Minimum
Recovery amount		$ 10,000,000
$10,000,000 to $40,000,000 | Pay Proceeds Agreement Member | Maximum
Recovery amount		$ 40,000,000
Over $40,000,000 | Pay Proceeds Agreement Member
Net recovery proceeds due to sellers (as a percent)		50.00%
Over $40,000,000 | Pay Proceeds Agreement Member | Minimum
Recovery amount		$ 40,000,000
Series B Convertible Preferred Stock | Registration Rights Agreement Member | Minimum
Percentage of registrable shares covered in resale registration statement (as a percent)	10.00%

ACQUISITIONS (Details 4)

ACQUISITIONS (Details 4)	Aug. 14, 2015	Jul. 16, 2015shares	Apr. 23, 2015USD ($)patent	Oct. 13, 2014USD ($)	Sep. 19, 2014USD ($)shares	Aug. 29, 2014USD ($)$ / sharesshares	Jun. 17, 2014USD ($)patent$ / sharesshares	Sep. 30, 2014USD ($)$ / shares	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)$ / shares	Sep. 30, 2015USD ($)patent	Sep. 30, 2015USD ($)item	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)$ / shares	Sep. 30, 2015USD ($)	Dec. 31, 2014USD ($)	Aug. 31, 2014USD ($)
Number of Patents (in patents)											369	7
Fair value of common stock issued														$ 281,000
Promissory note payment													$ 1,109,375	937,500
Acquisition of patents														6,850,800
Fully-diluted capitalization (as a percent)	55.00%
Impairment of goodwill										$ 2,144,488			0	$ 2,144,488
Goodwill									$ 4,573,450		$ 4,573,450	$ 4,573,450	4,573,450		$ 4,573,450	$ 4,894,208
Impairment of patent													766,498
Selene Communication Technologies
Number of Patents (in patents) | patent							3
Common stock issued (in shares) | shares							100,000
Consideration paid							$ 50,000
Fair value on grant date (in dollars per share) | $ / shares							$ 9.80
Fair value of common stock issued							$ 980,000
Intangible assets							990,000
Net working capital							37,000
Goodwill							3,000
Net purchase price							$ 1,030,000
Clouding Corp [Member]
Intangible assets																	$ 14,500,000
Goodwill																	1,296,000
Net purchase price																	$ 15,796,000
Gain on exchange in fair value adjustment									597,047				2,901,348
Impairment of patent									0				766,498
Cash						$ 1,400,000
Promissory Note						1,000,000
Common Stock						281,000
Earn Out Liability						13,115,000
Net purchase price						15,796,000
Clouding Corp [Member] | Level 3
Earnout liability, short-term									327,757		327,757	327,757	327,757		327,757
Earnout liability, long-term									6,222,895		$ 6,222,895	$ 6,222,895	6,222,895		6,222,895
TLI Communications LLC [Member]
Ownership interest held (as a percent)					100.00%
Intangible assets					$ 940,000
Goodwill					228,000
Net purchase price					$ 1,168,000
Medtech Entities
Ownership interest held (as a percent)				100.00%
Consideration paid				$ 1,000,000
Promissory note issued				9,000,000
Restricted common stock granted (in shares) | shares		200,000
Loss on extinguishment of debt									$ (654,000)				$ (654,000)
Intangible assets				12,800,000
Goodwill				2,700,000
Net purchase price				15,500,000
Patent Purchase Agreement Member | Clouding Corp [Member]
Consideration paid						1,400,000
Promissory note issued						$ 1,000,000
Restricted common stock granted (in shares) | shares						25,000
Net recovery proceeds due to sellers (as a percent)						50.00%
Fair value of restricted common stock						$ 281,000
Net revenues						$ 4,000,000
Interests Sale Agreement Member | Clouding Corp [Member]
Fair value on grant date (in dollars per share) | $ / shares						$ 11.24
Fair value of common stock issued						$ 281,000
Earn out liability booked															$ 2,148,000
Interests Sale Agreement Member | TLI Communications LLC [Member]
Common stock issued (in shares) | shares					60,000
Consideration paid					$ 350,000
Net recovery proceeds due to sellers (as a percent)					50.00%
Fair value on grant date (in dollars per share) | $ / shares								$ 13.63		$ 13.63				$ 13.63
Fair value of common stock issued								$ 818,000
Interests Sale Agreement Member | Medtech Entities
Outstanding amount after renegotiation				6,250,000
Debt reduction available upon early repayment				$ 750,000
Bridgestone | Patent Purchase Agreement Member
Number of Patents (in patents) | patent			43
Acquisition of patents			$ 3,500,000
Number of installments (in payments)			2
Maximum possible amount of future payments			$ 6,500,000
Fair value of patent assets acquired			$ 10,000,000
Holdco
Fully-diluted capitalization (as a percent)	45.00%

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Intangible Assets Details
Intangible Assets	$ 58,684,865	$ 49,914,360
Accumulated Amortization & Impairment	(14,931,649)	(6,550,528)
Intangible assets, net	$ 43,753,217	$ 43,363,832

INTANGIBLE ASSETS (Details 1)

INTANGIBLE ASSETS (Details 1)	Sep. 30, 2015USD ($)
Future amortization of intangible assets, net
2,015	$ 2,641,611
2,016	10,431,758
2,017	8,026,466
2,018	6,380,723
2,019	5,470,671
Thereafter	10,801,988
Total	$ 43,753,217

INTANGIBLE ASSETS (Details 2)

INTANGIBLE ASSETS (Details 2) - 9 months ended Sep. 30, 2015	Total	patent	item
Number of Patents		369	7
Earliest Expiration Date	3/10/2014
Median Expiration Date	12/1/2015
Latest Expiration Date	8/6/2022
Communication and PBX equipment
Number of Patents			17
Earliest Expiration Date	9/15/2016
Median Expiration Date	9/15/2015
Latest Expiration Date	1/22/2018
Network and data management
Number of Patents			60
Earliest Expiration Date	Expired
Median Expiration Date	10/5/2021
Latest Expiration Date	3/29/2029
Web page content translator and device-to-device transfer system [Member]
Number of Patents			5
Earliest Expiration Date	9/17/2021
Median Expiration Date	8/11/2022
Latest Expiration Date	8/19/2023
Telephony and data transactions [Member]
Number of Patents			35
Earliest Expiration Date	Expired
Median Expiration Date	1/31/2017
Latest Expiration Date	6/7/2020
Natural language interface [Member]
Number of Patents			4
Earliest Expiration Date	Expired
Median Expiration Date	10/2/2017
Latest Expiration Date	3/6/2023
Manufacturing schedules using adaptive learning [Member]
Number of Patents			4
Earliest Expiration Date	4/27/2020
Median Expiration Date	11/17/2023
Latest Expiration Date	7/18/2024
Asynchronous communications [Member]
Number of Patents			2
Earliest Expiration Date	11/14/2015
Median Expiration Date	9/9/2016
Latest Expiration Date	7/17/2017
Pharmaceuticals / tire pressure systems [Member]
Number of Patents			49
Earliest Expiration Date	Expired
Median Expiration Date	4/9/2017
Latest Expiration Date	7/26/2020
Automotive [Member]
Number of Patents			10
Earliest Expiration Date	Expired
Median Expiration Date	9/25/2017
Latest Expiration Date	8/27/2022
Medical technology [Member]
Number of Patents			137
Earliest Expiration Date	Expired
Median Expiration Date	6/1/2018
Latest Expiration Date	7/29/2029
Multicasting [Member]
Number of Patents			1
Earliest Expiration Date	Expired
Median Expiration Date	Expired
Latest Expiration Date	Expired
Centrifugal communications [Member]
Number of Patents			3
Earliest Expiration Date	3/13/2018
Median Expiration Date	3/13/2018
Latest Expiration Date	11/16/2023
Microsurgery equipment [Member]
Number of Patents			5
Earliest Expiration Date	Expired
Median Expiration Date	Expired
Latest Expiration Date	Expired
Communications [Member]
Number of Patents			3
Earliest Expiration Date	5/5/2018
Median Expiration Date	11/23/2020
Latest Expiration Date	11/28/2021
Telecommunications [Member]
Number of Patents			6
Earliest Expiration Date	6/17/2017
Median Expiration Date	6/17/2017
Latest Expiration Date	6/17/2017
Computer networking and operations [Member]
Number of Patents			31
Earliest Expiration Date	Expired
Median Expiration Date	12/21/2016
Latest Expiration Date	3/9/2018

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative)

1 Months Ended

3 Months Ended

9 Months Ended

Dec. 31, 2013USD ($)

Nov. 30, 2013USD ($)shares

Sep. 30, 2013USD ($)

Jun. 30, 2013USD ($)

Apr. 30, 2013USD ($)

Sep. 30, 2015USD ($)

Sep. 30, 2013USD ($)

Sep. 30, 2015

Sep. 30, 2015patent

Sep. 30, 2015item

Sep. 30, 2015USD ($)

Sep. 30, 2014USD ($)

Sep. 30, 2013USD ($)

Amortization expense

$ 2,884,269

$ 1,480,311

$ 8,511,730

$ 2,872,638

$ 2,872,638

Number of Patents

369

7

Impairment of patent

$ 766,498

Relay IP [Member]

Date of patent transaction

Apr. 1, 2013

Patent acquired, value

$ 350,000

CyberFone [Member]

Date of patent transaction

Apr. 1, 2013

Patent acquired, value

$ 1,135,512

Siemens Technology [Member]

Date of patent transaction

Jun. 1, 2013

Patent acquired, value

$ 1,000,000

14 US patents [Member]

Date of patent transaction

Sep. 1, 2013

Patent acquired, value

$ 1,100,000

four patents [Member]

Date of patent transaction

Nov. 1, 2013

Shares issued for patent acquisition | shares

150,000

Patent acquired, value

$ 718,500

Delphi [Member]

Date of patent transaction

Dec. 1, 2013

Patent acquired, value

$ 1,700,000

Minimum

Weighted average useful life, intangibles

1 year

Maximum

Weighted average useful life, intangibles

15 years

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - Common Stock Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Number of Warrants
Warrants, beginning balance	1,926,308
Granted	100,000
Exercised	5,000
Warrants, ending balance	2,021,308	1,926,308
Warrants Exercisable	2,021,308
Weighted Average Exercise Price
Weighted average exercise price, beginning balance	$ 4.1
Granted	7.44
Exercised	3.75
Weighted average exercise price, ending balance	4.27	$ 4.1
Weighted average fair value of warrants granted during the period	$ 3.19
Weighted Average Remaining Life
Weighted average remaining life, beginning balance		9 months 18 days
Granted	4 years 3 months 29 days
Weighted average remaining life, beginning balance	11 months 23 days

STOCKHOLDERS' EQUITY (Details 1

STOCKHOLDERS' EQUITY (Details 1) - $ / shares	Sep. 16, 2015	Sep. 30, 2015	Dec. 31, 2014
Number of Options
Granted	80,000
Common Stock Option [Member]
Number of Options
Options outstanding, beginning		3,017,690
Granted		425,000
Forfeited		462,330
Exercised		33,968
Options outstanding, ending		2,946,392	3,017,690
Options Exercisable		1,745,664
Options expected to vest		1,200,728
Weighted Average Exercise Price
Weighted average exercise price, beginning balance		$ 4.64
Granted		5.89
Forfeited		5.53
Exercised		3.25
Weighted average exercise price, ending balance		4.63	$ 4.64
Weighted average fair value of options granted during the period		$ 2.09
Weighted Average Remaining Life
Weighted Average Remaining Life, beginning			7 years 9 months 7 days
Granted		8 years 9 months 29 days
Weighted Average Remaining Life, ending		6 years 11 months 12 days

STOCKHOLDERS' EQUITY (Details N

STOCKHOLDERS' EQUITY (Details Narrative)	Sep. 21, 2015USD ($)item$ / sharesshares	Jul. 24, 2015shares	Jan. 29, 2015shares	Dec. 22, 2014shares	Oct. 16, 2014USD ($)	Oct. 06, 2014shares	Sep. 30, 2014USD ($)$ / sharesshares	Sep. 16, 2014shares	Jul. 18, 2014shares	Jun. 30, 2014USD ($)$ / sharesshares	Jun. 02, 2014shares	May. 02, 2014USD ($)shares	Apr. 22, 2014shares	Jun. 24, 2013	Oct. 01, 2012	Sep. 30, 2015$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2015shares	Mar. 31, 2015shares	Dec. 31, 2014$ / sharesshares	Sep. 30, 2014USD ($)$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)$ / shares	Sep. 17, 2015payment	Apr. 07, 2015period	Sep. 17, 2014shares	May. 01, 2014shares	Jul. 18, 2013$ / shares	Aug. 01, 2012shares	Dec. 07, 2011$ / sharesshares	Dec. 06, 2011$ / sharesshares
Authorized shares of common stock																200,000,000	200,000,000			200,000,000		200,000,000								200,000,000	75,000,000
Common stock par value | $ / shares																$ 0.0001	$ 0.0001			$ 0.0001		$ 0.0001						$ 0.0001		$ 0.0001	$ 0.001
Authorized shares of preferred stock																50,000,000	50,000,000			50,000,000		50,000,000								50,000,000
Preferred stock par value | $ / shares																$ 0.0001	$ 0.0001			$ 0.0001		$ 0.0001								$ 0.0001
Increase in number of outstanding shares of common stock				6,895,730
Shares reserved for issuance under plan																													10,000,000
Reverse split														one (1) for thirteen (13)	3-for-2
Number of monthly installments | period																									12
Issuance of Convertible Debt | $					$ 5,550,000																	$ 19,600,000
Stock compensation expense, vested warrants | $																	$ 556,205				$ 450,004	$ 1,971,323	$ 1,364,243
Common stock
Common stock issued			134,409								48,078
Shares issued upon exercise of options and warrants									26,722									33,968	5,000	29,230	84,652
Restricted Stock [Member]
Restricted shares issued							50,000	6,178		200,000			300,000
Fair value of restricted issuance | $							$ 281,000			$ 980,000
Shares issued, value per share | $ / shares							$ 5.62			$ 4.90											$ 5.62		$ 5.62
MedTech Development | Common stock
Common stock issued		200,000
Consultants [Member] | Common stock
Common stock issued	150,000
Stock Issued During Period, Value, Issued for Services | $	$ 334,500
Value of stock issued | $	$ 334,500
Shares issued, value per share | $ / shares	$ 2.23
Number of consultants | item	2
Consultant One Member | Common stock
Common stock issued	90,000
Consultant Two [Member] | Common stock
Common stock issued	60,000
Series B Preferred Stock [Member]
Authorized shares of preferred stock																											500,000
Preferred shares issued												782,000
Value, preferred shares and warrants issued | $												$ 2,807,380
Series B Preferred Stock [Member] | GRQ [Member]
Preferred shares agreement																										200,000
Percent vested upon execution of the GRQ Consulting Agreement																										50.00%
Percent vested after execution																										50.00%
Number of monthly installments | payment																								(6)
Preferred Stock converted to Common Stock																183,330
Restricted shares issued						100,000

STOCKHOLDERS' EQUITY - Warrants

STOCKHOLDERS' EQUITY - Warrants (Details Narrative) - USD ($)	Jan. 29, 2015	Oct. 16, 2014	May. 01, 2014	Apr. 24, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Apr. 20, 2014	Apr. 19, 2014
Issuance of Convertible Debt		$ 5,550,000					$ 19,600,000
Stock compensation expense, vested warrants					$ 556,205	$ 450,004	1,971,323	$ 1,364,243
Warrants
Value, preferred shares and warrants issued		$ 164,020
Warrants issued	100,000	258,998	511,790
Warrant Exercise Price	$ 7.44	$ 8.25	$ 3.75
Stock compensation expense, vested warrants					0		3,465
Unrecognized compensation expense, warrants					$ 0		$ 0
Warrant price									$ 5.75	$ 6.50
Proceeds from Warrant Exercises				$ 138,222

STOCKHOLDERS' EQUITY - Options

STOCKHOLDERS' EQUITY - Options (Details Narrative)	Sep. 16, 2015period$ / sharesshares	Apr. 07, 2015USD ($)period$ / sharesshares	Mar. 18, 2015period$ / sharesshares	Mar. 06, 2015period$ / sharesshares	Feb. 05, 2015period$ / sharesshares	Jan. 20, 2015	Oct. 31, 2014period$ / sharesshares	Sep. 16, 2014period$ / sharesshares	Aug. 29, 2014period$ / sharesshares	Jun. 15, 2014period$ / sharesshares	May. 15, 2014period$ / sharesshares	May. 14, 2014period$ / sharesshares	Apr. 15, 2014period$ / sharesshares	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)
Option issued | shares	80,000
Number of monthly installments | period		12
Expected term						6 years 6 months	5 years 9 months
Stock compensation expense, vested | $														$ 556,205	$ 450,004	$ 1,971,323	$ 1,364,243
Unrecognized compensation expense, options | $														$ 2,975,214		$ 2,975,214
Stock Option [Member]
Option issued | shares		280,000	20,000	20,000	25,000		160,000	60,000	290,000	40,000		80,000	20,000
Option term	10 years	10 years	5 years	5 years	5 years		10 years	5 years	10 years	5 years		10 years	5 years
Option price	$ 2.03	$ 6.76	$ 6.61	$ 7.37	$ 6.80		$ 6.40	$ 7.445	$ 5.62	$ 5.05		$ 4.165	$ 3.295
Percent vested upon execution of the GRQ Consulting Agreement		25.00%
Percent vested after execution		2.083%
Number of monthly installments | period	12		12	12	24			12		24			12
Number of annual installments | period							36		36			3
Expected term	5 years 6 months		3 years	3 years	3 years 3 months			3 years		3 years 3 months		6 years 6 months	3 years
Volatility	47.00%		41.00%	41.00%	47.00%	62.00%	53.00%	49.00%		50.00%		63.00%	51.00%
Discount rate	1.72%		0.92%	1.16%	0.92%	1.95%	1.78%	1.04%		1.05%		1.97%	0.84%
Monthly retainer | $		$ 27,000
Stock Option 2 [Member]
Option issued | shares							100,000					160,000
Option term							10 years					5 years
Option price							$ 6.40					$ 4.165
Number of annual installments | period							36					3
Expected term							5 years 9 months					3 years 6 months
Volatility							53.00%					50.00%
Discount rate							1.78%					1.00%
Stock Option 3 [Member]
Option issued | shares							680,000				290,000
Option term							10 years				10 years
Option price							$ 6.40				$ 4.165
Number of monthly installments | period							24
Number of annual installments | period											36
Expected term							5 years 9 months				6 years 6 months
Volatility							53.00%				63.00%
Discount rate							1.78%				1.97%
Stock Option 4 [Member]
Option issued | shares							30,000
Option term							5 years
Option price							$ 6.40
Number of monthly installments | period							24
Expected term							3 years 3 months
Volatility							49.00%
Discount rate							1.03%
Time Based Shares [Member]
Option issued | shares		70,000
Option price		$ 6.76
Expected term		6 years 3 months
Volatility		53.00%
Discount rate		1.53%
Time Based Shares [Member] | Minimum
Option price		$ 8.99
Performance Shares [Member]
Option issued | shares		70,000
Option price		$ 6.76
Expected term		10 years
Volatility		61.00%
Discount rate		1.89%
Performance Shares [Member] | Minimum
Option price		$ 10.14

COMMITMENTS AND CONTINGENCIES36

COMMITMENTS AND CONTINGENCIES (Details)	Jan. 31, 2015	Jan. 29, 2015USD ($)$ / sharesshares	Jun. 02, 2014shares	Jun. 30, 2015USD ($)period	Dec. 31, 2014USD ($)period	Sep. 30, 2015	Apr. 20, 2014$ / shares	Apr. 19, 2014$ / shares	Oct. 09, 2013
Monetization net revenues				$ 5,462,855
Common stock
Common stock issued (in shares) | shares		134,409	48,078
Warrants
Exercise price (in dollars per share) | $ / shares							$ 5.75	$ 6.50
Fortress
Warrant term		5 years
Warrant to purchase (in shares) | shares		100,000
Exercise price (in dollars per share) | $ / shares		$ 7.44
Common stock issued (in shares) | shares		134,409
Additional amount		$ 5,000,000
Minimum liquidity requirement		$ 1,000,000
Number of fiscal quarters (in quarters) | period				2	4
Fortress | Warrants
Percentage of ownership on common stock upon exercise of warrants		4.99%
Spangenberg Lockup Agreement | Common stock
Common stock issued (in shares) | shares		1,626,924
Spangenberg Lockup Agreement | Warrants
Common stock issued (in shares) | shares		48,078
Spangenberg Lockup Agreement | Preferred stock
Common stock issued (in shares) | shares		782,000
Minimum | Fortress
Monetization net revenues					$ 15,000,000
Minimum | Spangenberg Lockup Agreement
Percentage of Lock-up Shares		5.00%
Senior Secured Notes | Fortress
Original principal amount		$ 15,000,000
Monetization net revenues		15,000,000
Senior Secured Notes | Fortress | Additional Obligation Upon Milestone Achievement
Original principal amount		30,000,000
Initial Note | Fortress
Original principal amount		$ 15,000,000
Note term		42 months
Interest rate paid-in-kind (as a percent)	2.75%
Initial Note | LIBOR | Fortress
Interest rate		LIBOR
Spread (as a percent)		9.75%
Increase in interest rate (as a percent)		2.00%
Initial Note | 12-months LIBOR | Fortress
Effective rate (as a percent)						0.84735%
Convertible notes
Effective rate (as a percent)									11.00%
DBD | Fortress
Lock-up agreement period		12 months

COMMITMENTS AND CONTINGENCIES37

COMMITMENTS AND CONTINGENCIES (Details 2) - USD ($)	May. 01, 2014	Sep. 30, 2015
COMMITMENTS AND CONTINGENCIES
Lease term	7 years
Security Deposit	$ 7,564
Rent payment grace period	5 months
Lease termination option available	42th month of the lease
2015 (Nine Months)		$ 16,575
2,016		68,244
2,017		71,288
2,018		74,540
2,019		77,872
Thereafter		108,840
Total		$ 417,359

COMMITMENTS AND CONTINGENCIES38

COMMITMENTS AND CONTINGENCIES (Details 3) - Dominion Harbor Group, LLC - Subsequent Event	Oct. 30, 2015USD ($)periodpaymentshares
Loss Contingency, Information about Litigation Matters [Abstract]
Settlement agreement | $	$ 250,000
Settlement payment due | $	$ 50,000
Number of payments (in payments) | payment	8
Number of fiscal quarters (in quarters) | period	8
Restricted shares granted (in shares)	300,000
Vesting on May 4, 2016
Loss Contingency, Information about Litigation Matters [Abstract]
Restricted shares granted (in shares)	200,000
Vesting on November 3, 2016
Loss Contingency, Information about Litigation Matters [Abstract]
Restricted shares granted (in shares)	100,000

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details)	Nov. 16, 2015USD ($)	Oct. 30, 2015USD ($)periodpaymentshares	Oct. 23, 2015USD ($)	Oct. 16, 2015patent	Sep. 30, 2015patent	Sep. 30, 2015item	Nov. 15, 2015USD ($)
Number of Patents					369	7
Subsequent Event
Number of Patents | patent				31
Dominion Harbor Group, LLC | Subsequent Event
Loss Contingency, Information about Litigation Matters [Abstract]
Settlement agreement		$ 250,000
Settlement payment due		$ 50,000
Number of payments (in payments) | payment		8
Number of fiscal quarters (in quarters) | period		8
Restricted shares granted (in shares) | shares		300,000
Dominion Harbor Group, LLC | Vesting on May 4, 2016 | Subsequent Event
Loss Contingency, Information about Litigation Matters [Abstract]
Restricted shares granted (in shares) | shares		200,000
Dominion Harbor Group, LLC | Vesting on November 3, 2016 | Subsequent Event
Loss Contingency, Information about Litigation Matters [Abstract]
Restricted shares granted (in shares) | shares		100,000
Bridgestone | Subsequent Event
Loss Contingency, Information about Litigation Matters [Abstract]
Debt associated with purchase agreement							$ 10,000,000
Medtech Entities | Subsequent Event
Loss Contingency, Information about Litigation Matters [Abstract]
Payment of remaining balance of the note	$ 100,000
Forbearance Agreement | MedTech Development | Subsequent Event
Payment to extend due date			$ 100,000